[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 718009
1. Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L: Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol; 2006 Dec;19(12):1585-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia.
  • Previously, we reported that SALL4 was constitutively expressed in acute myeloid leukemia and SALL4 transgenic mice developed acute myeloid leukemia.
  • In this study, we aimed to survey SALL4 protein expression in benign and neoplastic hematopoietic tissues in addition to acute myeloid leukemia using immunostaining with a polyclonal anti-SALL4 antibody.
  • Reverse transcription-polymerase chain reaction was also performed to detect SALL4 mRNA expression on eight precursor B-cell lymphoblastic leukemia/lymphomas, 10 benign hematopoietic tissues, and seven hematopoietic cancer cell lines.
  • In neoplastic tissues, only precursor B-cell lymphoblastic leukemia/lymphomas had detectable SALL4 (12/16 at protein level, 7/8 at RNA level), similar to that observed in acute myeloid leukemia.
  • Of the seven cell lines examined, only those derived from acute myeloid leukemia and precursor B-cell lymphoblastic leukemia/lymphomas were positive.
  • The persistence of SALL4 expression in leukemic blasts in precursor B-cell lymphoblastic leukemia/lymphomas resembles to what we observed in acute myeloid leukemia, and correlates with the maturation arrest of these cells.
  • We have shown in our previous study that the constitutive expression of SALL4 in mice can lead to acute myeloid leukemia development.
  • The similar expression pattern of SALL4 in acute myeloid leukemia and B-cell lymphoblastic leukemia/lymphomas suggests that these two disease entities may share similar biological features and/or mechanisms of leukemogenesis.
  • More definite studies to investigate the role of SALL4 in the pathogenesis of B-cell lymphoblastic leukemia/lymphomas are needed in the future to address this question.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma / genetics. Plasmacytoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Cell Line, Tumor. Cell Separation. Flow Cytometry. Hematopoietic Stem Cells / metabolism. Hematopoietic Stem Cells / pathology. Humans. Immunoenzyme Techniques. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998462.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK063220
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / SALL4 protein, human; 0 / Transcription Factors
  •  go-up   go-down


2. Ye D, Wolff N, Li L, Zhang S, Ilaria RL Jr: STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood; 2006 Jun 15;107(12):4917-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of signal transducers and activators of transcription 5 (STAT5) in chronic myelogenous leukemia (CML) is controversial.
  • The remainder of P210/STAT5A(-/-) animals died from an acute B-cell lymphoblastic leukemia (ALL)-like disease (32%) or a CML/ALL mix (47%), reflecting impairment in the induction and maintenance of CML, which normally predominates in this mouse model.
  • Importantly, reconstitution of wild-type mice with BM cells coexpressing P210 and dominant-negative STAT5 also profoundly reduced the incidence of CML, without impairing the induction of ALL.
  • A greater understanding of the STAT5 target genes involved in CML induction may lead to new therapeutic targets that influence CML progenitor cell biology.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jan 15;14(2):232-44 [10652277.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jun;159(2):164-7 [15899391.001]
  • [Cites] J Exp Med. 2000 Mar 20;191(6):977-84 [10727459.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 May;3(5):299-305 [10964754.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):719-28 [10974037.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2269-76 [10979976.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2277-83 [10979977.001]
  • [Cites] Blood. 2001 Jan 1;97(1):277-87 [11133772.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Science. 2001 Aug 3;293(5531):876-80 [11423618.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2808-16 [11675355.001]
  • [Cites] Blood. 2002 Jan 15;99(2):479-87 [11781228.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):645-52 [11870241.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7622-7 [12032333.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2190-6 [12399961.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1549-61 [12400597.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3983-9 [12393407.001]
  • [Cites] Oncogene. 2002 Dec 9;21(56):8591-604 [12476306.001]
  • [Cites] Oncogene. 2002 Dec 9;21(56):8612-28 [12476308.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8804-16 [12483533.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):482-92 [12509448.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):30-3 [12547154.001]
  • [Cites] Eur J Haematol. 2003 Apr;70(4):235-9 [12656747.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17218-27 [12621061.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2 Suppl 2):80-2 [12783380.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5010-3 [12595307.001]
  • [Cites] Cytometry A. 2003 Aug;54(2):75-88 [12879454.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7389-95 [14576846.001]
  • [Cites] Curr Opin Hematol. 2004 Jan;11(1):35-43 [14676625.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S21-8 [15036938.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2965-72 [15070672.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Jun;18(3):525-43, vii [15271391.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):8037-47 [15340066.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Aug;75(8):3918-22 [211509.001]
  • [Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1069-78 [1691092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6 [7690960.001]
  • [Cites] Blood. 1994 Jan 1;83(1):43-50 [8274751.001]
  • [Cites] Gene Ther. 1994 Mar;1(2):136-8 [7584069.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):811-20 [8642285.001]
  • [Cites] Oncogene. 1996 Jul 18;13(2):247-54 [8710363.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1724-30 [8892675.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31704-10 [8940193.001]
  • [Cites] Genes Dev. 1997 Jan 15;11(2):179-86 [9009201.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14098-103 [9162035.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1768-76 [9292509.001]
  • [Cites] J Immunol. 1997 Nov 15;159(10):4720-8 [9366395.001]
  • [Cites] Cell. 1998 May 29;93(5):841-50 [9630227.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3780-92 [9808572.001]
  • [Cites] J Exp Med. 1999 Apr 19;189(8):1229-42 [10209040.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1399-412 [10224280.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4154-66 [10361113.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1108-12 [10419904.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):87-99 [15652752.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2118-25 [10706883.001]
  • (PMID = 16522816.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL61764
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / STAT5 Transcription Factor; 0 / Stat5a protein, mouse
  • [Other-IDs] NLM/ PMC1895818
  •  go-up   go-down


3. Yang HK, Yu HG: Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease. Korean J Ophthalmol; 2009 Dec;23(4):325-8
MedlinePlus Health Information. consumer health - Retinal Detachment.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia manifesting as acute Vogt-Koyanagi-Harada disease.
  • We describe a case of bilateral exudative retinal detachment associated with prodromal symptoms simulating the presentation of acute Vogt-Koyanagi-Harada disease that was eventually diagnosed as acute lymphoblastic leukemia.
  • A clinical diagnosis of incomplete type Vogt-Koyanagi-Harada disease was considered.
  • However, complete blood cell count showed a marked increase in the number of white blood cells and bone marrow examination revealed precursor B cell lymphoblastic leukemia.
  • Bilateral exudative retinal detachment associated with neurologic and auditory abnormalities may be a presenting sign of acute lymphoblastic leukemia.
  • Clinicians should be aware of the possibility of leukemia in such patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retinal Detachment / etiology. Uveomeningoencephalitic Syndrome / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fluorescein Angiography. Follow-Up Studies. Fundus Oculi. Humans. Male. Tomography, Optical Coherence. Visual Acuity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kaohsiung J Med Sci. 2001 Mar;17(3):150-5 [11486647.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):691-9 [12447107.001]
  • [Cites] Leuk Res. 2003 Jun;27(6):557-9 [12648516.001]
  • [Cites] Am J Ophthalmol. 1979 May;87(5):698-702 [443342.001]
  • [Cites] Ann Ophthalmol. 1979 Dec;11(12):1867-72 [299244.001]
  • [Cites] Am J Ophthalmol. 1987 Oct 15;104(4):364-72 [3661646.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Am J Ophthalmol. 1990 Apr 15;109(4):436-44 [2330946.001]
  • [Cites] Am J Ophthalmol. 1996 Jul;122(1):58-66 [8659599.001]
  • [Cites] Surv Ophthalmol. 1964 Oct;9:467-73 [14199728.001]
  • [Cites] Eur J Ophthalmol. 2005 Mar-Apr;15(2):284-6 [15812775.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Am J Ophthalmol. 2007 Aug;144(2):260-5 [17533104.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Retina. 2003 Dec;23(6):820-46; quiz 895-6 [14707834.001]
  • [Cites] Acta Haematol. 2000;104(1):46-9 [11111123.001]
  • [Cites] Am J Ophthalmol. 2001 May;131(5):647-52 [11336942.001]
  • [Cites] Retina. 2001;21(3):237-42 [11421013.001]
  • (PMID = 20046700.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2789964
  • [Keywords] NOTNLM ; Exudative retinal detachment / Leukemia / Vogt-Koyanagi-Harada disease
  •  go-up   go-down


Advertisement
4. Fernández-Teijeiro Alvarez A, Galán del Río P, Quintero Calcaño V, Montiano Jorge JI, Astigarraga Aguirre I, Navajas Gutiérrez A: [Subcutaneous nodules as a sign of malignant lymphoproliferative syndrome]. An Pediatr (Barc); 2009 Aug;71(2):148-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nódulos subcutáneos como forma de presentación de síndrome linfoproliferativo maligno.
  • Skin involvement in children with malignant processes usually appears at the same time or after the diagnosis of the primary tumour.
  • We present the case of a girl with cutaneous involvement prior to the diagnosis of a malignant lymphoproliferative process.
  • Immunophenotype confirmed the diagnosis of Precursor B Cell Lymphoblastic Leukemia-Lymphoma.
  • Although complete remission was achieved at the end of the induction chemotherapy according Euro-LB-02 protocol for stage IV, the patient presented a refractory leukaemia relapse thirteen months after diagnosis.
  • Differential diagnosis of malignant skin lesions in children, especially in infants, must include mainly secondary involvement of leukaemia, lymphoma, metastases of neuroblastoma or rhabdomyosarcoma and less frequently other primary processes.
  • In our patient with an isolated cutaneous presentation, the progression of her malignant lymphoproliferative process could be modified by the corticotherapy given before the definitive diagnosis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Infant. Lymphoproliferative Disorders / diagnosis. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19477699.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Boueva A, Bouvier R: Precursor B-cell lymphoblastic leukemia as a cause of a bilateral nephromegaly. Pediatr Nephrol; 2005 May;20(5):679-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic leukemia as a cause of a bilateral nephromegaly.
  • Nephromegaly and non-oliguric acute renal failure is an unusual manifestation of lymphoblastic infiltration of the kidneys.
  • We report the clinical history of a female child where a precursor B-cell lymphoblastic proliferation was diagnosed at the age of 21 months by a surgical renal biopsy for an unexplained bilateral nephromegaly.
  • Lymphoblastic infiltration should be suspected in any patient presenting with unexplained renal failure and enlarged kidneys.
  • [MeSH-major] Acute Kidney Injury / etiology. Acute Kidney Injury / pathology. Burkitt Lymphoma / complications. Kidney / pathology. Leukemic Infiltration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiol Med. 1990 Oct;80(4):564-7 [2244054.001]
  • [Cites] Radiology. 1982 Sep;144(4):759-66 [7111721.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):748-53 [3524795.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1120-1 [6883276.001]
  • [Cites] Radiology. 1982 Apr;143(1):207-10 [6950453.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1480-90 [11075849.001]
  • [Cites] Pediatr Dev Pathol. 2002 Jan-Feb;5(1):45-53 [11815868.001]
  • [Cites] Clin Nephrol. 1992 Sep;38(3):142-4 [1395166.001]
  • [Cites] Cancer. 1976 Dec;38(6):2588-92 [793711.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):423-6 [7545781.001]
  • [Cites] N Engl J Med. 1978 Dec 28;299(26):1446-8 [362210.001]
  • [Cites] AJR Am J Roentgenol. 1985 Sep;145(3):611-6 [3895872.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):795-804 [9669342.001]
  • [Cites] Am J Med. 1962 Feb;32:184-207 [14492019.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):868-75 [11392884.001]
  • [Cites] J Am Soc Nephrol. 1997 Aug;8(8):1348-54 [9259365.001]
  • [Cites] Cancer. 1974 Jan;33(1):203-5 [4810095.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):18-31 [11190804.001]
  • (PMID = 15714312.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Brown VI, Hulitt J, Fish J, Sheen C, Bruno M, Xu Q, Carroll M, Fang J, Teachey D, Grupp SA: Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res; 2007 Oct 15;67(20):9963-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
  • Understanding the pathogenesis of leukemia in the context of lymphopoiesis may reveal novel therapeutic targets.
  • Previously, we have shown that mTOR inhibitors (MTI) show activity in vitro and in preclinical models of both human and murine precursor B acute lymphoblastic leukemia (pre-B ALL), inhibiting cell proliferation and inducing apoptosis.
  • These MTI-mediated effects can be reversed by interleukin-7 (IL-7), an important regulator of early B-cell development.
  • TSLP is closely related to IL-7 and active in lymphopoiesis, but an effect of TSLP on leukemia cells has not been described.
  • We examined the effect of TSLP on pre-B ALL cells and their response to MTIs.
  • Here, we show that TSLP stimulates proliferation of pre-B ALL cell lines.
  • TSLP also partially reverses the effects of MTI on proliferation, apoptosis, and ribosomal protein S6 and 4E-BP1 phosphorylation in cell lines, with similar biological effects seen in some primary human lymphoblast samples.
  • These data show that TSLP can promote survival of pre-B ALL cells and antagonize the effects of MTIs.
  • These findings suggest that IL-7Ralpha chain is responsible for transducing the survival signal that overcomes MTI-mediated growth inhibition in pre-B ALL.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942929.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5K08-CA104882; United States / NCI NIH HHS / CA / K08 CA104882-04; United States / NCI NIH HHS / CA / K08 CA104882; United States / NCI NIH HHS / CA / CA104882-04; United States / NCI NIH HHS / CA / R01-CA102646
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carrier Proteins; 0 / Cytokines; 0 / Eif4ebp1 protein, mouse; 0 / Interleukin-7; 0 / Interleukin-7 Receptor alpha Subunit; 0 / Phosphoproteins; 0 / Protein Kinase Inhibitors; 0 / Recombinant Proteins; 0 / Ribosomal Protein S6; 0 / STAT5 Transcription Factor; 0 / thymic stromal lymphopoietin; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 3; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


7. Huh J, Moon H, Chung W: A case of ABL deletion in a patient with precursor B cell lymphoblastic leukemia. Ann Hematol; 2008 Mar;87(3):239-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ABL deletion in a patient with precursor B cell lymphoblastic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 9 / genetics. Gene Deletion. Genes, abl / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846770.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


8. Koren-Michowitz M, Rahimi-Levene N, Volcheck Y, Hardan I, Kornberg A: Rituximab monotherapy as interim therapy in precursor B-ALL adults during periods of hepatic toxicity: report of two cases. Am J Hematol; 2006 Dec;81(12):979-80
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab monotherapy as interim therapy in precursor B-ALL adults during periods of hepatic toxicity: report of two cases.
  • Precursor B-ALL blasts may be positive for CD20 in up to 50% of cases.
  • We report on two adult patients with precursor B-ALL who developed significant hepatic toxicity during induction chemotherapy.
  • Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation. Burkitt Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019690.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


9. Zhang LP, Cheng YF, Liu GL, Lu AD, Liu YR, Wang H: [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry]. Zhonghua Er Ke Za Zhi; 2005 Jul;43(7):481-5
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
  • OBJECTIVE: Flow cytometry may be used to detect minimal residual disease (MRD) in acute lymphoblastic leukemia because leukemic cells often display aberrant phenotypes when compared to normal cells.
  • CONCLUSION:. (1) Flow cytometry is a sensitive and specific method for detecting MRD of childhood ALL, and could predict the coming relapse. (2) Patients with MRD levels > 10(-3) had poor prognosis. (3) The levels of MRD at month 9 and 12 had prognostic value. (4) The value of antibody combinations consisting of CD(45)/CD(19)/CD(10)/CD(34) and CD(45)/CD(19)/CD(20)/CD(22) should be further investigated in patients without effective antibody combinations.
  • [MeSH-major] B-Lymphocyte Subsets / immunology. Flow Cytometry. Immunophenotyping. Neoplasm, Residual / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16083543.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Kahwash R, Rugg SS, Smith MD: Relapsing B-cell lymphoblastic leukemia in an adult presenting as an infiltrative cardiac mass with tamponade. J Am Soc Echocardiogr; 2007 Nov;20(11):1319.e1-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsing B-cell lymphoblastic leukemia in an adult presenting as an infiltrative cardiac mass with tamponade.
  • We present a case of a 51-year-old man with a history of bone-marrow transplantation for acute lymphoblastic leukemia who returned 4 months later with cardiac tamponade.
  • Surgical biopsy of the mass revealed early relapse with lymphoblasts derived from B-cell precursors.
  • We believe that this is the first description of relapsing B-cell acute lymphoblastic leukemia presenting as an intrathoracic mass with direct invasion of the adjacent cardiac structures causing tamponade physiology.
  • [MeSH-major] Cardiac Tamponade / etiology. Cardiac Tamponade / ultrasonography. Heart Neoplasms / etiology. Heart Neoplasms / ultrasonography. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / ultrasonography

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658241.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Seo-Mayer P, Kenney B, McNamara J, Stein J, Moeckel GW: Hematuria and decreased kidney function as initial signs of acute B-cell lymphoblastic leukemia. Am J Kidney Dis; 2010 Nov;56(5):1001-5
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematuria and decreased kidney function as initial signs of acute B-cell lymphoblastic leukemia.
  • We report the case of a 14-year-old boy who presented with hematuria and decreased kidney function as initial manifestations of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Hematuria / etiology. Kidney / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Renal Insufficiency / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Biopsy. Follow-Up Studies. Glomerular Filtration Rate. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20599308.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gotman LN, Iatsyk GA, Vorob'ev VI: [Diagnosis of cryptococcal encephalitis in a patient with mature B-cell lymphoblastic leukemia]. Ter Arkh; 2010;82(1):56-8
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of cryptococcal encephalitis in a patient with mature B-cell lymphoblastic leukemia].
  • The paper gives a case of successful treatment for cryptococcal meningoencephalitis in the presence of agranulocytosis, the diagnosis of which is based on the detection of abnormal MR signal foci by magnetic resonance imaging and identification of the cryptococcal antigen-glucuronoxylomannan in spinal fluid.
  • [MeSH-major] Cryptococcosis / diagnosis. Encephalitis / diagnosis. Magnetic Resonance Imaging / methods. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Antigens, Fungal / analysis. Cryptococcus neoformans / immunology. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364703.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Fungal
  •  go-up   go-down


13. Blin N, Méchinaud F, Talmant P, Garand R, Boutard P, Dastugue N, McIntyre EA, Harousseau JL, Avet-Loiseau H: Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia. Leukemia; 2008 May;22(5):1056-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature B-cell lymphoblastic leukemia with MLL rearrangement: an uncommon and distinct subset of childhood acute leukemia.
  • [MeSH-major] Leukemia, B-Cell / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007578.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


14. Shivarov V, Stoimenov A, Galabova I, Balatzenko G, Guenova M: Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia. Int J Lab Hematol; 2009 Feb;31(1):106-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very early onset of an acute myeloid leukemia in an adult patient with B-cell lymphoblastic leukemia.
  • We report on a case of a 30-year-old male with acute B-lymphoblastic leukemia (B-ALL) with immunophenotype CD19(+), CD22(+), CD20(+), CD10(+), with aberrant expression of CD13 and CD117, and IgH gene rearrangements.
  • The case is the first report of a very early emergence of myeloid leukemia during the induction treatment for B-ALL in an adult patient.
  • Different pathogenetic mechanisms are discussed - clonal evolution or selection, lineage switch or development of a de novo or therapy-induced leukemia.
  • [MeSH-major] Leukemia, B-Cell / complications. Leukemia, Myeloid, Acute / complications


15. Kim MJ, Yoon HS, Lim G, Kim SY, Lee HJ, Suh JT, Lee J, Lee WI, Park TS: ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. Cancer Genet Cytogenet; 2010 Jan 15;196(2):184-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review.
  • Here we describe a fifth case of ABL1 deletion without BCR/ABL1 rearrangement in an adolescent patient with precursor B-cell lymphoblastic leukemia (B-ALL) and review the relevant literature.
  • It is not clear how ABL1 deletion affects leukemogenesis; however, it is plausible that ABL1 deletion without BCR/ABL1 rearrangement is a rare but recurrent genetic abnormality in precursor B-ALL patients.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Gene Deletion. Gene Rearrangement. Leukemia, B-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20082857.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 24
  •  go-up   go-down


16. Řezáčová M, Vávrová J, Vokurková D: Ionizing Radiation Sensitizes Leukemic MOLT-4 Cells to TRAIL-induced Apoptosis. Acta Medica (Hradec Kralove); 2008;51(2):101-105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, leukemia cells studied to date have shown variable susceptibility to TRAIL.
  • Our study demonstrates that cells of acute T-lymphoblastic leukemia MOLT-4 are resistant to TRAIL and that ionizing radiation in the therapeutically achievable dose of 1 Gy sensitizes TRAIL-resistant cells MOLT-4 to the TRAIL-induced apoptosis by increase in death receptors for TRAIL DR5.
  • When TRAIL is applied after the irradiation in the time of increased DR5 positivity more efficient cell killing is achieved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28550838.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Czech Republic
  • [Keywords] NOTNLM ; Apoptosis / DR5 / Ionizing radiation / Leukemia / TRAIL
  •  go-up   go-down


17. Smith MA, Morton CL, Carol H, Gorlick RG, Kang MH, Keir ST, Kolb EA, Lock RB, Maris JM, Houghton PJ: Pediatric Preclinical Testing Program (PPTP) testing of the CENP-E inhibitor GSK923295A. J Clin Oncol; 2009 May 20;27(15_suppl):10015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The PPTP includes a molecularly characterized in vitro panel of cell lines (n = 27) and in vivo panel of xenografts (n = 60) representing most of the common types of childhood solid tumors and childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: GSK923295A demonstrated potent in vitro activity against the PPTP cell line panel with a median IC50 of 27 nM (range 12 nM to > 10 μM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962529.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers.
  • Flow cytometry was negative for CD45 and all common epithelial, T-cell and B-cell markers, but was positive for CD138 and p63(VS38c).
  • The diagnosis was stage IVBE PBL.
  • The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.
  • Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.
  • We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).
  • A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Fauzdar A, Mahajan A, Jain D, Mishra M, Raina V: Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia: A case report.
  • : e21000 Background: Chromosome abnormalities of leukemia cells have important prognostic significance in childhood acute lymphoblastic leukemia (ALL).
  • B-cell precursor acute lymphoblastic leukemia (BCP-ALL) ETV6/RUNX1 (alias TEL/AML1) is most frequent i.e.
  • We report two new cases with Pre B- cell ALL without ETV6/RUNX1 rearrangement, showing amplification of AML1 gene detected by FISH analysis.
  • RESULTS: In first case a 3-year girl with four copies of AML (RUNX1) gene were observed in 95% of the cell with normal two copies of TEL (ETV6) gene in both interphase and metaphase FISH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Yeh C, Ma W, Kantarjian H, Zhang ZJ, Cortes J, Albitar M: BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):7028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7028 Background: The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase.
  • We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance.
  • Total nucleic acids were purified and subjected to two rounds of PCR analysis, with the first PCR designed to eliminate amplification of the wild-type, non-translocated ABL gene.
  • HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control.
  • RESULTS: We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961401.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • Our published data showed that T-ALL phenotype patients fared poorly with 5 year survival of 27% versus 83% for precursor B-ALL (Recent Advances Research Update: 2006, 7; 1, P 51-56).
  • OBJECTIVES: We reviewed all patients diagnosed with T-ALL to assess risk classification according to NCI criteria, type of therapy received, overall survival and causes of mortality.
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Median WBCs 50,000/Cmm (range: 1.500-619,000/Cmm) and positive CNS at diagnosis 10/52 (20%).
  • Further risk and response stratification in addition to intensification of therapy for T-cell ALL in our center may prove to be beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • The continual reassessment method (CRM) was used to determine the maximum tolerated dose (MTD) from 4 pre-defined dose levels.
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.
  • All pts had pre-B ALL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14623 Background: Notch signaling is an evolutionary-conserved pathway in vertebrates and invertebrates which is involved many developmental processes, including cell fate decisions, apoptosis, proliferation, and stem-cell self renewal.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • RESULTS: Our data show that ANTP/DN MAML fusion protein, TR4 contains signals for proper cell targeting, internalization and nuclear transport.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lee K, Bang J, Kim K: Proteome analysis of malignant pleural effusion. J Clin Oncol; 2009 May 20;27(15_suppl):e22194

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty microliters of pleural effusions(PEs) from 3 patients with non-small cell lung cancer(NSCLC) and 3 patients with tuberculous pleurisy(TBC) were used for proteome analysis.
  • Among the identified proteins, we found the biomarker candidates that significantly have different expression levels in malignant effusion; apolipoprotein B precursor, vitronectin, complement factor B, histidine-rich glycoprotein precursor, coagulation factor II precursor variant.
  • CONCLUSIONS: We found that several pleural effusion proteins may serve as potential biomarker candidates for differential diagnosis between maligant and tuberculous pleural effusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963631.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Zuo Z, Jones DM, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Medeiros LJ, Luthra R, Chen SS: A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A nine-gene predictor of therapy response in adult Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
  • There was no statistical difference in age, initial peripheral blood white cell and BM blast counts, and initial normalized BCR/ABL1 levels between groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961387.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Mukhopadhyay A, Gupta P, Mukhopadhyay S, Dey S, Basak J, Pandey R: Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country. J Clin Oncol; 2009 May 20;27(15_suppl):10046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Result of adolescent acute lymphoblastic leukemia protocol (MCP 841) from a developing country.
  • : 10046 Background: Acute Lymphatic Leukemia is a curable disease in the range of 80 - 90% in developed countries by aggressive protocol like BFM, St. Judes' but result is much less in adolescence age group (60-70%).
  • CONCLUSIONS: The data of acute lymphatic leukemia in adolescent is not satisfactory as compared to other pediatric patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962472.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Iacobucci I, Storlazzi C, Lonetti A, Ferrari A, Messina M, Cilloni D, Papayannidis C, Baccarani M, Foà R, Martinelli G: IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report. J Clin Oncol; 2009 May 20;27(15_suppl):11005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IKZF1 (IKAROS) deletions as a prognostic marker in BCR-ABL1 positive acute lymphoblastic leukemia patients: A GIMEMA ALL WP Report.
  • : 11005 Expression of BCR-ABL1 in hematopoietic stem cells can alone induce a chronic myeloid leukemia (CML) but cooperating oncogenic lesions are required for the generation of a blastic leukemia.
  • To identify oncogenic sub-microscopic lesions that cooperate with BCR-ABL1 to induce ALL, by high resolution single nucleotide polymorphism (SNP) arrays (250K NspI and SNP 6.0, Affymetrix) we studied 106 patients (pts) with de novo adult BCR-ABL1-positive ALL.
  • A variable number of nucleotides (patient-specific) were inserted at the conjunction and maintained with fidelity at the time of relapse.
  • Gene expression profiling analysis of pts with IKZF1 deletion vs wild-type pts identified a unique signature characterized by a down-regulation of genes involved in pre-B-cell differentiation (e.g.
  • VPREB1, VPREB3, IGLL3, BLK), demonstrating that genomic IKZF1 alterations have a strong impact on trascriptoma and contribute to an impaired B-cell differentiation.
  • Univariate analysis showed that the IKZF1 deletion is a negative prognostic marker influencing the cumulative incidence of relapse (10.1 months for pts with deletion vs 56.1 months for wild-type pts, p=0.0103) and disease-free survival (DFS) (10.1 months vs 32.1 months, respectively, p=0.0229).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ikawa Y, Sugimoto N, Koizumi S, Yachie A, Saikawa Y: Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene. J Clin Oncol; 2009 May 20;27(15_suppl):10045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter DNA methylation of CD10 in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene.
  • While CD10 negativity reflects an earlier stage of B-cell development, complete IgH gene rearrangements (VDJ<sub>H</sub>) show more mature IgH status.
  • METHODS: CD10-negative infant ALL with MLL/AF4, CD10-positive infant ALL with germ-line MLL, CD10-positive pre-B ALL cell line, infant AML (M5) with MLL/AF9 and pediatric AML (M2) with AML1/ETO were analyzed for VDJ<sub>H</sub> status and methylation of CD10 gene promoters.
  • Bisulfite sequencing of CD 10 type 1 and 2 promoters identified more than 84% of methylated CpG dinucleotides in all three CD10-negative infant ALL cases with MLL/AF4.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962471.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yang J, Zhou X, Wang B, Gao C, Zhang RD, Li B: [Severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene: report of two cases and literature review]. Zhonghua Xue Ye Xue Za Zhi; 2009 Sep;30(9):615-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene: report of two cases and literature review].
  • OBJECTIVE: To improve the understanding of severe hypercalcemia complicated in acute lymphoblastic leukemia (ALL) with E2A-HLF fusion gene, and to explore the mechanism of pathogenesis and the relationship between the special gene translocation and severe hypercalcemia.
  • RESULTS: Two patients with E2A-HLF fusion gene, which is generated by t(17;19) (q22, p13) translocation, suffered relapse of leukemia three months after chemotherapy, and developed severe hypercalcemia.
  • In B cell lymphoblastic leukemia with E2A-HLF fusion gene, the fusion gene showed be closely monitored for evaluating the disease situation.
  • [MeSH-major] DNA-Binding Proteins / genetics. Hypercalcemia / etiology. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954622.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / E2a-Hlf fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Transcription Factors
  •  go-up   go-down


30. Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, Soverini S, Papayannidis C, Baccarani M, Foà R, Martinelli G: Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. J Clin Oncol; 2009 May 20;27(15_suppl):7049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients.
  • : 7049 Since the activation-induced cytidine deaminase (AID) enzyme can target non-immunoglobulin (Ig) genes and may even act as a genome-wide mutator, we investigated AID expression in BCR-ABL1-positive ALL and in chronic myeloid leukemia (CML) at the time of progression to blast crisis.
  • On the 61 de novo adult BCR-ABL1-positive ALL patients (pts), AID mRNA and protein were detected in 36 (59%); their expression correlated with BCR-ABL1 transcript levels and disappeared after treatment with tyrosine kinase inhibitors at the time of remission.
  • Different isoforms of AID were identified: 13/61 (21%) pts expressed the full-length isoform; 19/61 (31%) co-expressed the wild-type and different AID splice variants with deaminase activity (AIDΔE4a, with a 30 bp deletion of exon 4; AIDΔE4, with the exon 4 deletion; AIDins3, with the retention of intron 3-4); 4/61 (7%) expressed the AIDΔE3-E4 isoform without deaminase activity (deletion of exons 2 and 3).
  • Patients who expressed wild-type AID had a higher number of alterations compared to AID-negative (median copy number alteration of 14 versus 4. respectively, p < 0.03).
  • Our findings show that BCR-ABL1-positive ALL cells aberrantly express different isoforms of AID that can act as mutator outside the Ig gene loci in promoting genetic instability in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961429.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ambati S, Chamyan G, Restrepo R, Escalon E, Fort J, Pefkarou A, Khatib ZA, Dehner LP: Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Sep;51(3):433-5
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosai-Dorfman disease following bone marrow transplantation for pre-B cell acute lymphoblastic leukemia.
  • A child with acute pre-B cell lymphoblastic leukemia underwent haploidentical bone marrow transplantation (BMT) after first relapse.
  • Only one previous example of acute lymphoblastic leukemia in childhood has been reported with R-D disease.
  • [MeSH-major] Bone Marrow Transplantation / adverse effects. Graft vs Host Disease / etiology. Histiocytosis, Sinus / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Rosai-Dorfman disease.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18493991.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / S100 Proteins
  •  go-up   go-down


32. Naunheim MR, Nahed BV, Walcott BP, Kahle KT, Soupir CP, Cahill DP, Borges LF: Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. Clin Neurol Neurosurg; 2010 Sep;112(7):575-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature.
  • Intracerebral hemorrhage (ICH) contributes significantly to the morbidity and mortality of patients suffering from acute leukemia.
  • While ICH is often identified in autopsy studies of leukemic patients, it is rare for ICH to be the presenting sign that ultimately leads to the diagnosis of leukemia.
  • We report a patient with previously undiagnosed acute precursor B-cell lymphoblastic leukemia (ALL) who presented with diffuse encephalopathy due to ICH in the setting of an acute blast crisis.
  • The diagnosis of ALL was initially suspected, because of the hyperleukocytosis observed on presentation, then confirmed with a bone marrow biopsy and flow cytometry study of the peripheral blood.
  • This case demonstrates that the presence of hyperleukocytosis in a patient with intracerebral hemorrhage should raise clinical suspicion for acute leukemia as the cause of the ICH.
  • [MeSH-major] Blast Crisis / diagnosis. Intracranial Hemorrhages / diagnosis. Leukemia, Biphenotypic, Acute / diagnosis
  • [MeSH-minor] Benzamides. Blood Cell Count. Diagnosis, Differential. Flow Cytometry. Humans. Imatinib Mesylate. In Situ Hybridization. Leukocyte Count. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20493628.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


33. Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, Poppe B, Van Roy N, Vandesompele J, Graux C, Uyttebroeck A, Boogaerts M, De Moerloose B, Benoit Y, Selleslag D, Billiet J, Robert A, Huguet F, Vandenberghe P, De Paepe A, Marynen P, Hagemeijer A: A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia; 2005 Mar;19(3):358-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias.
  • Chromosomal translocations with breakpoints in T-cell receptor (TCR) genes are recurrent in T-cell malignancies.
  • These translocations involve the TCRalphadelta gene (14q11), the TCRbeta gene (7q34) and to a lesser extent the TCRgamma gene at chromosomal band 7p14 and juxtapose T-cell oncogenes next to TCR regulatory sequences leading to deregulated expression of those oncogenes.
  • Here, we describe a new recurrent chromosomal inversion of chromosome 7, inv(7)(p15q34), in a subset of patients with T-cell acute lymphoblastic leukemia characterized by CD2 negative and CD4 positive, CD8 negative blasts.
  • This is the first report of a recurrent chromosome rearrangement targeting the HOXA gene cluster in T-cell malignancies resulting in deregulated HOXA gene expression (particularly HOXA10 and HOXA11) and is in keeping with a previous report suggesting HOXA deregulation in MLL-rearranged T- and B cell lymphoblastic leukemia as the key factor in leukaemic transformation.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 7 / genetics. DNA-Binding Proteins / genetics. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Transcriptional Activation / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674412.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / HOXA11 protein, human; 0 / Homeodomain Proteins; 140441-81-2 / HOXA10 protein, human
  •  go-up   go-down


34. Moulin AP, Bucher M, Pournaras JA, Nguyen C, Ambresin A: Fluorescein and indocyanine green angiography findings in B cell lymphoblastic leukemia mimicking acute central serous chorioretinopathy. Klin Monbl Augenheilkd; 2010 Apr;227(4):342-4
Hazardous Substances Data Bank. INDOCYANINE GREEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescein and indocyanine green angiography findings in B cell lymphoblastic leukemia mimicking acute central serous chorioretinopathy.
  • [MeSH-major] Choroid Neoplasms / pathology. Fluorescein Angiography / methods. Indocyanine Green. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retinal Neoplasms / pathology. Retinoscopy / methods

  • Genetic Alliance. consumer health - Central Serous Chorioretinopathy.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408096.001).
  • [ISSN] 1439-3999
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] IX6J1063HV / Indocyanine Green
  •  go-up   go-down


35. Wandroo F, Bell A, Darbyshire P, Pratt G, Stankovic T, Gordon J, Lawson S, Moss P: ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. Int J Lab Hematol; 2008 Apr;30(2):149-57
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
  • ZAP-70 is, however, expressed in adult B cell chronic lymphocytic leukemia where it correlates with a poor prognosis.
  • We wished to determine if ZAP-70 is also expressed in pediatric B cell malignancy.
  • A quantitative PCR assay for ZAP-70 expression was established and ZAP-70 expression in a range of human B cell lines was compared with expression in the Jurkat T cell line.
  • ZAP-70 expression was then determined in bone marrow lymphoblasts obtained from 12 patients with pre-B cell acute lymphoblastic leukemia (ALL).
  • ZAP-70 expression was not detected in mature B cell lines but was detected in pre-B cell lines at a level comparable to that seen in T cells.
  • ZAP-70 expression was strongly expressed in nine of the 12 cases of primary pre-B cell lymphoblastic leukemia.
  • The T cell-associated protein kinase ZAP-70 is highly expressed in pre-B lineage cells and most cases of pre-B acute lymphoblastic leukemia.
  • ZAP-70 expression may hold prognostic value for pre-B ALL and raises the prospect of a novel therapeutic target.
  • [MeSH-major] B-Lymphocytes / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cells, B-Lymphoid / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism
  • [MeSH-minor] Adolescent. Blotting, Western. Bone Marrow Cells / metabolism. Cell Line, Transformed. Cell Line, Tumor. Child. Child, Preschool. Female. Flow Cytometry. Gene Expression. Humans. Jurkat Cells. Male. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18333847.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


36. Chu PG, Loera S, Huang Q, Weiss LM: Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study. Am J Clin Pathol; 2006 Oct;126(4):534-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage determination of CD20- B-Cell neoplasms: an immunohistochemical study.
  • We studied 61 CD20- B-cell lymphomas, including 29 cases of precursor B-cell lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/B-LBL), 25 cases of CD20- recurrent mature B-cell lymphoma after rituximab therapy, and 7 cases of CD20- diffuse large B cell lymphoma (DLBCL).
  • We used markers specific for B lineage: CD79a, Pax-5, OCT.2, and BOB.1.
  • The percentages of cases expressing Pax-5, CD79a, OCT.2, and BOB.1 in CD20- recurrent mature B-cell lymphomas after rituximab treatment were 88% (21/24), 84% (21/25), 81% (17/21), and 73% (16/22), respectively.
  • CD79a and Pax-5 should be used as the first-line B lineage-specific markers for rituximab-treated CD20- mature B-cell lymphomas.
  • [MeSH-major] Antigens, CD20 / analysis. B-Lymphocytes / pathology. Burkitt Lymphoma / pathology. Cell Lineage. Immunohistochemistry / methods. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938666.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


37. Liu GL, Zhang LP, Lu AD: [Clinical analysis of short period chemotherapy in childhood acute B-cell lymphoblastic leukemia, standard-risk type]. Zhonghua Er Ke Za Zhi; 2006 Dec;44(12):948-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of short period chemotherapy in childhood acute B-cell lymphoblastic leukemia, standard-risk type].
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17254469.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Herling M, Patel KA, Hsi ED, Chang KC, Rassidakis GZ, Ford R, Jones D: TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol; 2007 Jul;31(7):1123-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.
  • The high expression of the T-cell oncogene TCL1 in B-cell tumors and the emergence of B-cell lymphomas in TCL1-transgenic mice suggest a pathogenetic role for this kinase coregulator in B-cell malignancies.
  • We compared the expression of TCL1 in B-cell tumors with their differentiation stage.
  • As with normal B-cell subsets, uniform TCL1 expression was characteristic of tumors of pregerminal center derivation such as precursor B-cell lymphoblastic leukemia/lymphoma (85%, 47/55) and mantle cell lymphoma (84%, 49/58), and was more variable in follicular lymphoma (57%, 28/49).
  • Large B-cell lymphoma was less frequently positive for TCL1 (36%, 18/50), especially among cases of the activated B-cell type.
  • All types of Hodgkin lymphoma, splenic marginal zone lymphoma, and post-germinal center-derived tumors, including plasma cell myeloma and MALT lymphoma, were negative for TCL1, except for 1 case.
  • In normal B cells, cell lines and primary B-cell tumor samples, TCL1 downmodulation occurred after prolonged cytokine treatment and/or B-cell receptor stimulation.
  • In contrast to mature T-cell tumors where TCL1 expression is always indicative of an activating TCL1 gene translocation, TCL1 expression in B-cell tumors parallels its regulation in non-neoplastic B cells.
  • Therefore, TCL1 expression can be used diagnostically as an indicator of the differentiation stage of a given B-cell tumor.
  • [MeSH-major] B-Lymphocytes / metabolism. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / metabolism. Proto-Oncogene Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592280.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


39. Jiang NG, Zhu HL, Zeng TT, Su J, Zhang Y, Jia YQ: [Flow cytometric analysis of cerebrospinal fluid in the diagnosis of central nervous system leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul;41(4):664-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Flow cytometric analysis of cerebrospinal fluid in the diagnosis of central nervous system leukemia].
  • OBJECTIVE: To evaluate the value of flow cytometric immunophenotyping of cerebrospinal fluid (CSF) cells in the diagnosis of central nervous system leukemia.
  • Antibody panles CD19/CD34/CD3/CD45, CD117/CD34/CD5/CD45, CD7/CD34/ CD19/CD45, CD7/CD3/HLA-DR/CD45, CD20/CD10/CD3/CD45, and anti-g/anti-lambda/CD19/CD45 were used in determining cell composition and detecting abnormal cells.
  • The results of flow cytometry were compared with conventional cell count and morphology.
  • Among the 59 samples taken from patients with lymphocyte neoplasm, CD19 + blast cells were found in the CSF in 13 patients with B-cell lymphoblastic leukemia; CD7+ blast cells were found in 4 T-ALL cases; and monoclonal CD19+ cells were found in 6 other types of lymphoma cases.
  • In the 32 patients with clinically diagnosed myeloid leukemia, CD117+ myeloid cells were found in the CSF of 7 patients and B cell blast cells were found in 2 CML cases.
  • The cell concentrations of the eight samples in which abnormal cells were only detected by flow cytometry were lower than 10 X 10(6)/L.
  • The immunophenotyping results of two ALL patients were still positive when morphologic results had become negative after chemotherapy.
  • CONCLUSION: Flow cytometric analysis of CSF may be helpful in the diagnosis of meningeal leukemia.
  • It has higher positive rate and better accuracy than cytomorphology and cell count.
  • [MeSH-major] Meningeal Neoplasms / cerebrospinal fluid. Meningeal Neoplasms / secondary. Precursor Cell Lymphoblastic Leukemia-Lymphoma / cerebrospinal fluid. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Flow Cytometry. Humans. Leukemia, Myeloid, Acute / cerebrospinal fluid. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20848792.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Boatsman EE, Fu CH, Song SX, Moore TB: Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation. J Pediatr Hematol Oncol; 2010 Mar;32(2):e57-60
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia effect on infant lymphoblastic leukemia relapsed after sibling hematopoietic stem cell transplantation.
  • INTRODUCTION: Infant acute lymphoblastic leukemia (ALL) is considered a high-risk entity.
  • By morphology, infant ALL is classified as a lymphoid lineage leukemia; however, its physiologic behavior has brought many to consider it a pathologic hybrid between lymphoid leukemia and myeloid leukemias.
  • As such, standard of care currently employs the use of chemotherapeutic agents used commonly in ALL protocols and agents typically reserved for the treatment of myelogenous lineage leukemias.
  • The role of hematopoietic stem cell transplantation and graft-versus-leukemia effect in these patients has not been well studied.
  • CASE PRESENTATION: An earlier healthy 9-week-old Hispanic male diagnosed with precursor B-cell lymphoblastic leukemia was treated with protocol P9407 and matched sibling hematopoietic stem cell transplantation.
  • CONCLUSION: Traditionally, graft-versus-leukemia effect was thought to contribute therapeutically little to the treatment of ALL by hematopoietic stem cell transplantation (HSCT).
  • The effects of graft-versus-leukemia immunologic phenomenon in our patient with infant acute lymphoblastic leukemia underscore the potential that infant ALL may not be entirely the same biologic entity as standard pediatric ALL and may be more responsive than understood earlier.
  • Therapeutic response and appearance of GVHD after the withdrawal of immunosuppression in this patient provides evidence that graft-versus-leukemia effect may play a role in disease control in infant ALL after HSCT.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168246.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Lv L, Wu C, Sun H, Zhu S, Yang Y, Chen X, Fu H, Bao L: Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population. Eur J Haematol; 2010 Jun;84(6):506-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined 677CC/1298AC genotypes of methylenetetrahydrofolate reductase (MTHFR ) reduce susceptibility to precursor B lymphoblastic leukemia in a Chinese population.
  • It has been suggested that two MTHFR polymorphisms, 677C>T and 1298A>C, influence risk of acute lymphoblastic leukemia (ALL).
  • Here, we report a case-control study of 127 Chinese patients with adult precursor B lymphoblastic leukemia (B-ALL) to examine correlation between the MTHFR polymorphisms and B-ALL susceptibility in adults.
  • [MeSH-major] Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Single Nucleotide. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20374270.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


42. Cobaleda C, Sánchez-García I: B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays; 2009 Jun;31(6):600-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin.
  • B-cell acute lymphoblastic leukaemia (B-ALL) is a clonal malignant disease originated in a single cell and characterized by the accumulation of blast cells that are phenotypically reminiscent of normal stages of B-cell differentiation.
  • B-ALL origin has been a subject of continuing discussion, given the fact that human disease is diagnosed at late stages and cannot be monitored during its natural evolution from its cell of origin, although most B-ALLs probably start off with chromosomal changes in haematopoietic stem cells.
  • However, the cells responsible for maintaining the disease appear to differ between the different types of B-ALLs and this remains an intriguing and exciting topic of research, since these cells have been posited to be responsible for resistance to conventional therapies, recurrence and dissemination.
  • The results from these different reconstitution experiments and their interpretations are compared in this review in the context of normal B-cell developmental plasticity.
  • [MeSH-major] B-Lymphocytes / physiology. Leukemia, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Differentiation / physiology. Humans. Neoplastic Stem Cells / cytology. Neoplastic Stem Cells / physiology. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444834.001).
  • [ISSN] 1521-1878
  • [Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology
  • [ISO-abbreviation] Bioessays
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


43. Mårtensson IL, Almqvist N, Grimsholm O, Bernardi AI: The pre-B cell receptor checkpoint. FEBS Lett; 2010 Jun 18;584(12):2572-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pre-B cell receptor checkpoint.
  • During the development of progenitor B cells to mature B cells that express a membrane-bound antibody, the B cell receptor (BCR), the cells undergo selection at several checkpoints, which ensures that a diverse antibody repertoire is generated and that the BCRs recognise foreign-, but not self-, antigens.
  • In this review, we consider the pre-BCR checkpoint.
  • Mutations or alterations that affect this checkpoint underpin the development of pre-B cell leukemias, primary immunodeficiency, and possibly, systemic autoimmunity.
  • [MeSH-major] Pre-B Cell Receptors / immunology. Precursor Cells, B-Lymphoid / immunology
  • [MeSH-minor] Animals. Autoimmunity / genetics. Cell Differentiation / immunology. Cell Membrane / immunology. Gene Rearrangement, B-Lymphocyte. Humans. Immunologic Deficiency Syndromes / genetics. Immunologic Deficiency Syndromes / immunology. Mice. Models, Immunological. Mutation. Signal Transduction / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20420836.001).
  • [ISSN] 1873-3468
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Pre-B Cell Receptors
  • [Number-of-references] 60
  •  go-up   go-down


44. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M, Saito N, Yang SM, Iwamoto C, Okamura J, Liu KY, Huang XJ, Lu DP, Shultz LD, Harada M, Ishikawa F: CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia; 2008 Jun;22(6):1207-13
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
  • In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction.
  • To understand the origin of malignant cells in primary human B-precursor acute lymphocytic leukemia (B-ALL), we established a novel in vivo xenotransplantation model.
  • In each of the three cases studied, transplantation of CD34+CD38+CD19+ cells resulted in the development of B-ALL in secondary recipients, demonstrating self-renewal capacity.
  • The identification of CD34+CD38+CD19+ self-renewing B-ALL cells proposes a hierarchy of leukemia-initiating cells (LICs) distinct from that of AML.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Hematopoietic Stem Cells / pathology. Neoplastic Stem Cells / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Animals. Animals, Newborn. Cell Differentiation. Cell Lineage. Child. Flow Cytometry. Graft Survival. Humans. Immunophenotyping. Infant. Mice. Mice, Inbred NOD. Mice, SCID. Transplantation, Heterologous. Tumor Cells, Cultured. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418410.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


45. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D'Amico G: Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol; 2006 Sep;34(9):1219-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Cytokine-induced killer (CIK) cells are ex vivo expanded cells enriched in CD3(+)CD56(+) natural killer T (NKT) cells with major histocompatibility-unrestricted cytotoxicity against several tumoral targets, except B-lineage acute lymphoblastic leukemia (B-ALL).
  • We redirected CIK cells cytotoxicity toward B-ALL with a chimeric receptor specific for the CD19 antigen and then explored if modified-CIK cells maintain the same chemotactic properties of freshly isolated NKT cells, whose trafficking machinery reflects their preferential localization into the sites of B-ALL infiltration.
  • MATERIAL AND METHODS: CIK cells were expanded ex vivo for 21 days and analyzed for expression of adhesion molecules and chemokine receptors regulating adhesion and homing toward leukemia-infiltrated tissues.
  • Anti-CD19 chimeric receptor-modified CIK cells became cytotoxic against B-ALL cells (mean lysis, 60%) and showed, after exposure to a CXCL12 gradient, high capacity to adhere and transmigrate through endothelial cells and to invade Matrigel.
  • CONCLUSION: The potential capacity to localize into leukemia-infiltrated tissues of anti-CD19 chimeric receptor-redirected CIK cells, together with their ability to efficiently kill B-ALL cells, suggests that modified-CIK cells represent a valuable tool for leukemia immunotherapy.
  • [MeSH-major] Antigens, CD19 / immunology. Burkitt Lymphoma / immunology. Cell Movement / immunology. Cytotoxicity, Immunologic. Killer Cells, Lymphokine-Activated / immunology. Recombinant Fusion Proteins / immunology. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939815.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


46. Boag JM, Beesley AH, Firth MJ, Freitas JR, Ford J, Brigstock DR, de Klerk NH, Kees UR: High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br J Haematol; 2007 Sep;138(6):740-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia.
  • In recent years microarrays have been used extensively to characterize gene expression in acute lymphoblastic leukaemia (ALL).
  • Few studies, however, have analysed normal haematopoietic cell populations to identify altered gene expression in ALL.
  • We used oligonucleotide microarrays to compare the gene expression profile of paediatric precursor-B (pre-B) ALL specimens with two control cell populations, normal CD34(+) and CD19(+)IgM(-) cells, to focus on genes linked to leukemogenesis.
  • One gene, connective tissue growth factor (CTGF, also known as CCN2), had exceptionally high expression, which was confirmed in three independent leukaemia studies.
  • Protein studies using Western blot analysis demonstrated the presence of CTGF in ALL cell-conditioned media.
  • These findings indicate that CTGF is secreted by pre-B ALL cells and may play a role in the pathophysiology of this disease.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Immediate-Early Proteins / genetics. Intercellular Signaling Peptides and Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760805.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / Culture Media, Conditioned; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 139568-91-5 / Connective Tissue Growth Factor
  •  go-up   go-down


47. Li S: Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin Ther Targets; 2005 Apr;9(2):329-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.
  • The participation of Src kinases in the induction of BCR-ABL-induced B cell acute lymphoblastic leukaemia (B-ALL), but not chronic myeloid leukaemia (CML), demonstrates cell type-specific signalling in Philadelphia chromosome-positive (Ph+) leukaemias.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Drug Delivery Systems / methods. Protein Kinase Inhibitors / therapeutic use. src-Family Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934919.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / src-Family Kinases
  • [Number-of-references] 114
  •  go-up   go-down


48. Kawano Y, Yoshikawa S, Minegishi Y, Karasuyama H: Pre-B cell receptor assesses the quality of IgH chains and tunes the pre-B cell repertoire by delivering differential signals. J Immunol; 2006 Aug 15;177(4):2242-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-B cell receptor assesses the quality of IgH chains and tunes the pre-B cell repertoire by delivering differential signals.
  • It is well understood how a variety of Ig H and L chains, components of BCR, are generated in the DNA level during B cell development.
  • Here we show that muH chains produced by pre-B cells display a wide spectrum of ability to form the pre-BCR, which is composed of muH and surrogate light (SL) chains and is crucial for B cell development.
  • The level of surface pre-BCR expression varies among pre-B cells, depending on the ability of their muH chains to pair with SL chains.
  • The higher the level of pre-BCR expression by pre-B cells, the stronger their pre-BCR signaling, and the better they proliferate and differentiate.
  • Thus, the extent of survival, proliferation, and differentiation of individual pre-B cells is primarily determined by the SL-pairing ability of their muH chains.
  • Furthermore, IgH chains with higher potential to assemble with IgL chains appear to be positively selected and amplified through the assessment of their ability to pair with SL chains at the pre-BCR checkpoint before the assembly into the BCR.
  • These results indicate that the pre-BCR assesses the quality of muH chains and tunes the pre-B cell repertoire by driving the preferential expansion and differentiation of cells with the higher quality of muH chains.
  • [MeSH-minor] Animals. Cell Line. Hematopoietic Stem Cells / immunology. Hematopoietic Stem Cells / metabolism. Mice. Mice, Mutant Strains. Pre-B Cell Receptors. Receptors, Antigen, B-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887984.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Membrane Glycoproteins; 0 / Pre-B Cell Receptors; 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


49. Lovisa F, Mussolin L, Corral L, Pillon M, Cazzaniga G, Biondi A, Rosolen A: IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. Lab Invest; 2009 Oct;89(10):1182-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis.
  • We recently reported that minimal residual disease (MRD) and minimal disseminated disease (MDD), assessed by long-distance PCR (LD-PCR) for t(8;14), are negative prognostic factors in mature B-cell acute lymphoblastic leukemia (B-ALL) and in Burkitt's lymphoma (BL).
  • The aim of our study was to evaluate the characteristics of patient-specific immunoglobulin (Ig) gene rearrangements as RQ-PCR targets for MRD analysis, in order to extend MRD studies to those patients who are not eligible for the LD-PCR assay.
  • In 87% of patients (84% of B-ALLs, 95% of BLs) at least one sensitive target was available.
  • All PCR targets identified at diagnosis were preserved at relapse.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, B-Lymphocyte, Light Chain. Immunoglobulin Heavy Chains / genetics. Immunoglobulin kappa-Chains / genetics. Leukemia, B-Cell / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668242.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


50. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, Nadal N, Taviaux S, Poppe B, Luquet I, Baranger L, Eclache V, Radford I, Barin C, Mozziconacci MJ, Lafage-Pochitaloff M, Antoine-Poirel H, Charrin C, Perot C, Terre C, Brousset P, Dastugue N, Broccardo C: Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood; 2010 Apr 15;115(15):3089-97
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.
  • PAX5 is the main target of somatic mutations in acute B lymphoblastic leukemia (B-ALL).
  • Contrary to cases with PAX5 fusions, deletions were associated with complex karyotypes and common recurrent translocations.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Cytogenetic Analysis. Mutation / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160164.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human
  •  go-up   go-down


51. Harb JG, Chyla BI, Huettner CS: Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood; 2008 Apr 1;111(7):3760-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The kinase inhibitors imatinib mesylate and dasatinib are the preferred treatment for Philadelphia chromosome-positive (Ph+) leukemias, and they are highly successful in the chronic phase of chronic myeloid leukemia (CML).
  • However, they are not efficient in Ph+ B-cell acute lymphoblastic leukemia (B-ALL).
  • Ph+ leukemia cells are highly resistant to apoptosis, and evidence from cell lines and primary cells suggest Bcl-xL as a critical mediator of resistance to apoptosis: however, this concept has never been rigorously tested in an animal model.
  • In the first model, Ph+ B-ALL and loss of Bcl-xL expression are coinduced; in the second model, leukemia is induced with expression of Bcl-xL protein well above the levels found in wild-type lymphoblasts.
  • These models reveal an unexpected role for Bcl-xL in cell-cycle entry and the proliferation of tumor cells.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jun 15;99(12):4531-9 [12036885.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2309-15 [17496201.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7765-75 [12420213.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4410-9 [12393582.001]
  • [Cites] Leuk Res. 2004 May;28 Suppl 1:S21-8 [15036938.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] N Engl J Med. 1982 Nov 11;307(20):1231-6 [7133054.001]
  • [Cites] Science. 1984 Nov 30;226(4678):1097-9 [6093263.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Cell. 1986 Oct 10;47(1):19-28 [2875799.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1820-8 [8104532.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2182-91 [7514531.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1506-10 [7878471.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5287-91 [7777499.001]
  • [Cites] Development. 1994 Oct;120(10):3033-42 [7607090.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):381-91 [8627151.001]
  • [Cites] J Biol Chem. 1996 Mar 15;271(11):6306-12 [8626425.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):811-20 [8642285.001]
  • [Cites] Science. 1996 Sep 6;273(5280):1384-6 [8703072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9545-52 [8790367.001]
  • [Cites] J Cell Biochem. 1996 Jan;60(1):23-32 [8825412.001]
  • [Cites] Blood. 1997 Jan 15;89(2):601-9 [9002964.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6979-90 [9003774.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7239-44 [9207075.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2301-11 [9278319.001]
  • [Cites] Blood. 1998 Feb 15;91(4):1391-8 [9454770.001]
  • [Cites] Oncogene. 1998 Jan 22;16(3):335-48 [9467959.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6589-96 [10597263.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):57-60 [10615128.001]
  • [Cites] J Exp Med. 2000 Mar 20;191(6):977-84 [10727459.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1958-68 [10815921.001]
  • [Cites] Mol Endocrinol. 2000 Jul;14(7):1038-52 [10894153.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1933-9 [10961897.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2269-76 [10979976.001]
  • [Cites] Oncologist. 2000;5(5):405-15 [11040277.001]
  • [Cites] Development. 2000 Nov;127(22):4949-58 [11044408.001]
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23572-80 [11323429.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Immunity. 1996 Mar;4(3):291-9 [8624819.001]
  • [Cites] Blood. 1996 May 15;87(10):4368-75 [8639797.001]
  • [Cites] Blood. 1998 May 1;91(9):3379-89 [9558396.001]
  • [Cites] Cell. 1998 May 29;93(5):841-50 [9630227.001]
  • [Cites] J Exp Med. 1998 Dec 7;188(11):2067-74 [9841920.001]
  • [Cites] N Engl J Med. 1999 Apr 29;340(17):1330-40 [10219069.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1399-412 [10224280.001]
  • [Cites] Blood. 2005 Jan 1;105(1):324-34 [15331442.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3303-11 [15626746.001]
  • [Cites] Nat Immunol. 2005 Aug;6(8):836-43 [16025120.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4898-906 [16493008.001]
  • [Cites] N Engl J Med. 2006 Jun 15;354(24):2531-41 [16775234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14651-2 [17003111.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Blood. 2007 Jan 15;109(2):747-55 [16954505.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5766-74 [12411494.001]
  • (PMID = 18216295.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007209; United States / NHLBI NIH HHS / HL / HL-07209
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Bcl2l1 protein, mouse; 0 / bcl-X Protein
  • [Other-IDs] NLM/ PMC2275032
  •  go-up   go-down


52. Bao L, Gross SA, Ryder J, Wang X, Ji M, Chen Y, Yang Y, Zhu S, Irons RD: Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases. Int J Hematol; 2009 May;89(4):431-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult precursor B lymphoblastic leukemia in Shanghai, China: characterization of phenotype, cytogenetics and outcome for 137 consecutive cases.
  • Acute lymphoblastic leukemia (ALL) accounts for 20-30% of adult leukemia in the West.
  • However, detailed studies of B-cell-specific ALL in adult Asian populations are lacking.
  • We diagnosed and characterized 137 consecutive cases of precursor B lymphoblastic leukemia (precursor B-cell ALL) presented to our laboratory in Shanghai using the WHO 2001 classification system.
  • In contrast to Western studies, females (71) outnumbered males (66) partly due to an increased prevalence of the CD10- pro B-cell phenotype.
  • Females with a CD10- pro B-cell phenotype exhibited significantly better overall survival than males.
  • The most common cytogenetic abnormality was the Philadelphia chromosome (PH/BCR/ABL) which was found in approximately 37% of the cases.
  • Cases of precursor B cell ALL lacking the PH/BCR/ABL genotype exhibited a pronounced age-dependent, gender prevalence with a modal age in the sixth decade for females compared to the second decade for males.
  • These findings suggest significant geographic heterogeneity in precursor B-cell ALL which may be of both etiological and therapeutic significance.
  • [MeSH-major] Chromosome Aberrations. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):263-73 [10674898.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Jun;13(3):358-63 [15972120.001]
  • [Cites] Int J Hematol. 2008 Sep;88(2):165-73 [18648906.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Leukemia. 1993 Feb;7(2):147-51 [8426467.001]
  • [Cites] Blood. 2005 May 1;105(9):3449-57 [15657178.001]
  • [Cites] Hematology. 2004 Oct-Dec;9(5-6):369-76 [15763976.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1151-68 [7858247.001]
  • [Cites] Turk J Haematol. 2006 Sep 5;23(3):151-7 [27265483.001]
  • [Cites] Am J Hematol. 2002 Dec;71(4):291-9 [12447959.001]
  • [Cites] Br J Haematol. 2004 Feb;124(3):275-88 [14717774.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):323-32 [16280661.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Expert Opin Biol Ther. 2006 Oct;6(10):1011-22 [16989583.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] Ann Hematol. 2001 Sep;80(9):510-5 [11669298.001]
  • [Cites] Cancer Treat Rep. 1982 Jan;66(1):37-42 [7053264.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1834-40 [11753602.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1408-13 [17062730.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):329-42 [9517504.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Jan;3(1):1-7 [2069905.001]
  • [Cites] Blood. 1991 Nov 1;78(9):2411-8 [1932753.001]
  • [Cites] Leukemia. 1994 Jan;8(1):186-9 [8289486.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2393-417 [8625065.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Jul 15;40(2):171-85 [2766242.001]
  • [Cites] Eur J Haematol. 2006 Jul;77(1):35-45 [16573742.001]
  • (PMID = 19322628.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


53. Gudowius S, Recker K, Laws HJ, Dirksen U, Tröger A, Wieczorek U, Furlan S, Göbel U, Hanenberg H: Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Padiatr; 2006 Nov-Dec;218(6):327-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL.
  • BACKGROUND: Contemporary risk adapted treatment protocols for childhood acute lymphoblastic leukemia (ALL) rely on accurate risk assessment strategies for disease re-occurrence by incorporating clinical parameters as well as immunological, molecular and cytogenetic features of the blasts at initial manifestation.
  • PATIENTS AND METHODS: In order to identify target antigen structures, we analyzed the immunological expression profiles of blasts from 181 patients with B-cell precursor ALL treated at our institution in 11 years according to the CoALL-92/97/03 protocols.
  • Blasts were classified according to the EGIL guidelines as 9 proB-, 110 common (c-) and 62 preB-ALL.
  • CD10 was expressed on all c-/preB-ALL and absent on proB-ALL cells.
  • CD20 was expressed on 11-37 % of B-cell precursor ALL samples.
  • CD34 positive blasts were found in 89, 83 and 68 % of patients with proB-, c- and preB-ALL, respectively.
  • < 20 % CD45(+) blasts were found in 11, 19 and 18 % of patients with proB-, c- and preB-ALL.
  • CD33(+) was expressed on 33, 29 and 21 % of patients samples with proB-, c- and preB-ALL.
  • Analyses of the immunological profile of blasts in 9 consecutive children with relapse revealed that the antigen expression profile varied little compared to the initial diagnosis for CD10, CD19, CD22 and HLA-DR.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD19 / analysis. Burkitt Lymphoma / immunology. HLA-DR Antigens / analysis. Immunotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Sialic Acid Binding Ig-like Lectin 2 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080335.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / HLA-DR Antigens; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


54. Lee RV, Braylan RC, Rimsza LM: CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia. Am J Clin Pathol; 2005 Jan;123(1):119-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.
  • We used flow cytometry to determine the CD58 expression on nonmalignant B cells at different stages of maturation in the bone marrow and compared it with that of blasts in adult and pediatric precursor B-cell acute lymphoblastic leukemia (B-ALL).
  • The mean fluorescence intensity (MFI) of CD58 expression decreased significantly as nonmalignant B cells differentiated in the bone marrow from an early to a mature stage.
  • Few nonneoplastic B cells at a mid or mature stage of development expressed CD58 MFI values comparable to those seen in leukemic cases.
  • Early-stage nonneoplastic B-cell precursors expressed relatively higher CD58 levels, which frequently overlapped with the variable level of CD58 expression observed among leukemic blasts.
  • As a group, however, the malignant precursor B-ALL cells showed significantly higher expression of CD58 than nonmalignant B-cell populations at any maturational stage.
  • These findings support the potential usefulness of CD58 expression in the diagnosis and monitoring of precursor B-ALL, but only when blasts express high levels of CD58.
  • [MeSH-major] Antigens, CD58 / analysis. B-Lymphocytes / physiology. Bone Marrow Cells / physiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762287.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, CD58
  •  go-up   go-down


55. Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E: Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology; 2008 Oct 21;71(17):1350-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
  • Whereas its presumed mode of action is inhibition of T cell/monocyte entry into the brain, little is known about its specific effect on B cells, which are increasingly recognized to participate in MS pathogenesis.
  • We determined numbers of mature and immature lymphocyte subsets by flow cytometry for CD3, CD4, CD8, CD19, CD138, and CD10 in 111 samples.
  • We analyzed marker transcripts for immature hematopoietic cells by quantitative PCR for CD34, Vprebeta1 (pre-B lymphocyte gene 1), and DNTT (terminal deoxynucleotidyltransferase) in 65 samples.
  • RESULTS: Natalizumab therapy increased CD19(+) mature B cells more than other lymphocytes/monocytes in blood (2.8-fold versus 1.3-1.8-fold increase in cells/microL; p < 0.01).
  • Even greater was the increase of immature CD19(+)CD10(+) pre-B cells (7.4-fold; p < 0.01).
  • CONCLUSIONS: Circulating B cells and especially pre-B cells are most prominently elevated among the studied immune cell subsets, raising the possibility that the effects and side effects of natalizumab are partly mediated by actions on B cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. B-Lymphocytes / pathology. Multiple Sclerosis, Relapsing-Remitting / immunology. Multiple Sclerosis, Relapsing-Remitting / therapy. Precursor Cells, B-Lymphoid / metabolism. Precursor Cells, B-Lymphoid / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cell Migration Inhibition / immunology. Humans. Lymphocyte Count. Natalizumab. Prospective Studies. Time Factors

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936427.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Natalizumab
  •  go-up   go-down


56. Hendriks RW, Kersseboom R: Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells. Semin Immunol; 2006 Feb;18(1):67-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells.
  • Signals from the precursor-B cell receptor (pre-BCR) are essential for selection and clonal expansion of pre-B cells that have performed productive immunoglobulin heavy chain V(D)J recombination.
  • In the mouse, the downstream signaling molecules SLP-65 and Btk cooperate to limit proliferation and induce differentiation of pre-B cells, thereby acting as tumor suppressors to prevent pre-B cell leukemia.
  • In contrast, recent observations in human BCR-ABL1(+) pre-B lymphoblastic leukemia cells demonstrate that Btk is constitutively phosphorylated and activated by the BCR-ABL1 fusion protein.
  • [MeSH-major] B-Lymphocytes / metabolism. Carrier Proteins / physiology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Hematopoietic Stem Cells / metabolism. Phosphoproteins / physiology. Protein-Tyrosine Kinases / physiology. Tumor Suppressor Proteins / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300960.001).
  • [ISSN] 1044-5323
  • [Journal-full-title] Seminars in immunology
  • [ISO-abbreviation] Semin. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / Carrier Proteins; 0 / Phosphoproteins; 0 / Tumor Suppressor Proteins; EC 2.7.10.1 / Agammaglobulinaemia tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 104
  •  go-up   go-down


57. Bankovich AJ, Raunser S, Juo ZS, Walz T, Davis MM, Garcia KC: Structural insight into pre-B cell receptor function. Science; 2007 Apr 13;316(5822):291-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural insight into pre-B cell receptor function.
  • The pre-B cell receptor (pre-BCR) serves as a checkpoint in B cell development.
  • In the 2.7 angstrom structure of a human pre-BCR Fab-like fragment, consisting of an antibody heavy chain (HC) paired with the surrogate light chain, the "unique regions" of VpreB and lambda5 replace the complementarity-determining region 3 (CDR3) loop of an antibody light chain and appear to "probe" the HC CDR3, potentially influencing the selection of the antibody repertoire.
  • Biochemical analysis indicates that the pre-BCR is impaired in its ability to recognize antigen, which, together with electron microscopic visualization of a pre-BCR dimer, suggests ligand-independent oligomerization as the likely signaling mechanism.
  • [MeSH-major] Membrane Glycoproteins / chemistry. Receptors, Antigen, B-Cell / chemistry
  • [MeSH-minor] Animals. Complementarity Determining Regions / chemistry. Complementarity Determining Regions / physiology. Crystallography, X-Ray. Humans. Immunoglobulin Heavy Chains / chemistry. Immunoglobulin Heavy Chains / physiology. Immunoglobulin Light Chains / chemistry. Immunoglobulin Light Chains / physiology. Immunoglobulin Light Chains, Surrogate. Mice. Models, Molecular. Pre-B Cell Receptors. Protein Conformation. Recombinant Proteins. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431183.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 2H32/ 2H3N
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007290
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Light Chains, Surrogate; 0 / Membrane Glycoproteins; 0 / Pre-B Cell Receptors; 0 / Receptors, Antigen, B-Cell; 0 / Recombinant Proteins
  •  go-up   go-down


58. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, Jumaa H, Müschen M: BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene; 2006 Feb 16;25(7):1118-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
  • Pre-B lymphoblastic leukemia cells carrying a BCR-ABL1 gene rearrangement exhibit an undifferentiated phenotype.
  • Comparing the genome-wide gene expression profiles of normal B-cell subsets and BCR-ABL1+ pre-B lymphoblastic leukemia cells by SAGE, the leukemia cells show loss of B lymphoid identity and aberrant expression of myeloid lineage-specific molecules.
  • Consistent with this, BCR-ABL1+ pre-B lymphoblastic leukemia cells exhibit defective expression of IKAROS, a transcription factor needed for early lymphoid lineage commitment.
  • As shown by inducible expression of BCR-ABL1 in human and murine B-cell precursor cell lines, BCR-ABL1 induces the expression of a dominant-negative IKAROS splice variant, termed IK6.
  • Comparing matched leukemia sample pairs from patients before and during therapy with the BCR-ABL1 kinase inhibitor STI571 (Imatinib), inhibition of BCR-ABL1 partially corrected aberrant expression of IK6 and lineage infidelity of the leukemia cells.
  • To elucidate the contribution of IK6 to lineage infidelity in BCR-ABL1+ cell lines, IK6 expression was silenced by RNA interference.
  • Upon inhibition of IK6, BCR-ABL1+ leukemia cells partially restored B lymphoid lineage commitment.
  • Therefore, we propose that BCR-ABL1 induces aberrant splicing of IKAROS, which interferes with lineage identity and differentiation of pre-B lymphoblastic leukemia cells.
  • [MeSH-major] Alternative Splicing. Ikaros Transcription Factor / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Benzamides. Cell Line, Tumor. Cell Lineage / genetics. Cell Nucleus / chemistry. Fusion Proteins, bcr-abl. Gene Expression Profiling. Gene Silencing. Humans. Imatinib Mesylate. Mice. Piperazines / pharmacology. Protein Kinase Inhibitors / pharmacology. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / pharmacology

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16205638.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / IKZF1 protein, human; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 148971-36-2 / Ikaros Transcription Factor; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


59. Correa-González LC, Mandeville PB, Manrique-Dueñas J, Alejo-González F, Salazar-Martínez A, de Pérez-Ramírez OJ, Hernández-Sierra JF: [Prognostic value of pre-B immunophenotype in early treatment response among acute pediatric lymphoblast leukemia patients]. Gac Med Mex; 2005 Nov-Dec;141(6):477-82
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic value of pre-B immunophenotype in early treatment response among acute pediatric lymphoblast leukemia patients].
  • [Transliterated title] Valor pronóstico del inmunofenotipo en la respuesta temprana de la leucemia aguda linfoblástica pre-B en niños.
  • OBJECTIVE: To determine the prognostic value of preB immunophenotype and its variants on early treatment response among of acute pediatric lymphoblast leukemia.
  • PATIENTS AND METHODS: A case-control study nested in a cohort was carried out with male and female patients 15 years and younger with recently diagnosed pre-B lymphoblast leukemia.
  • A panel of B, T, monoclonal antibodies of the myelo-monocytic and megakaryocytic cell type was used.
  • We identified 29 cases with late pre-B immune phenotype, 19 cases with common pre B and 6 cases with early preB immunophenotype.
  • No association was found between the pre-B immunophenotype, age and leukocyte count with early treatment response (p=0.264).
  • CONCLUSIONS: We need to pay special emphasis on early treatment response in children with lymphoblast leukemia as our study did not corroborate the common finding that clinical factors and immune phenotype can be predictive factors.
  • [MeSH-major] Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381501.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


60. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, Kushida Y, Ishida T, Tanaka T: Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse. Int J Clin Oncol; 2010 Feb;15(1):112-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse.
  • A lineage switch in leukemia, in which the leukemic cell lineage at onset converts to another lineage at a later time, is an uncommon type of hybrid (mixed) leukemia regarded as a variation of bilineage leukemia.
  • We present a case of a 60-year-old female diagnosed with precursor B cell acute lymphoblastic leukemia (ALL), whose markers in flow cytometry shifted from their original status of CD19+, 22+, 79a+, 13+, HLA-DR+, and TdT+.
  • This phenotypical conversion from B-ALL to hybrid leukemia featuring monocytoid characteristics is known as a lineage switch.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / pathology. Leukemia, Monocytic, Acute / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Biomarkers, Tumor / blood. Bone Marrow / pathology. Cell Lineage. Female. Humans. Immunophenotyping. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):2023-6 [8609712.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):311-21 [15803157.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):261-4 [3552021.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1223-7 [16085566.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2088-95 [2553159.001]
  • [Cites] Haematologica. 2004 Aug;89(8):ECR28 [15339697.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jan 15;164(2):118-21 [16434313.001]
  • [Cites] Am J Hematol. 2000 Sep;65(1):72-4 [10936868.001]
  • [Cites] Clin Haematol. 1986 Aug;15(3):811-27 [3536242.001]
  • [Cites] Blood Rev. 1988 Mar;2(1):9-15 [3289656.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 15;168(2):146-9 [16843104.001]
  • [Cites] Br J Haematol. 1993 May;84(1):49-60 [7687860.001]
  • (PMID = 20066454.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


61. Bernard N, Devevey L, Jacquemont C, Chrétien P, Helissey P, Guillosson JJ, Arock M, Nafziger J: A new model of pre-B acute lymphoblastic leukemia chemically induced in rats. Exp Hematol; 2005 Oct;33(10):1130-9
Hazardous Substances Data Bank. N-NITROSO-N-BUTYLUREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new model of pre-B acute lymphoblastic leukemia chemically induced in rats.
  • OBJECTIVE: Although B acute lymphoblastic leukemia (B-ALL) is the most common leukemia among children, no chemically inducible model of this leukemia has yet been described in vivo.
  • METHODS: Leukemia was chemically induced in male WKAH/Hkm rats by a nitrosourea derivative, N-butylnitrosourea (BNU), an alkylating agent, administered orally 5 days a week for 24 weeks.
  • Development of leukemia was monitored by clinical observation, follow-up of blood parameters, and appearance of blast cells in peripheral blood samples.
  • The phenotype of the leukemia was determined by cytological examination, cytochemical reactions, and by immunophenotyping of bone marrow cells using various markers.
  • The feasibility of leukemia transplantation was investigated.
  • RESULTS: We observed the appearance of acute leukemia in 60% of the rats treated with BNU.
  • Of these, 65% developed pre-B-ALL, which was serially transplantable to healthy WKAH/Hkm male rats.
  • Clonality determined by immunoglobulin gene rearrangement sequencing disclosed that the pre-B-ALL were mostly oligoclonal.
  • CONCLUSION: This new in vivo model of inducible pre-B-ALL might be useful for investigating the effects of co-initiating or promoting agents suspected to be involved in leukemia development, and for disclosing new molecular events leading to leukemogenic processes.
  • [MeSH-major] Carcinogens / toxicity. Leukemia, Experimental / pathology. Nitrosourea Compounds / toxicity. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219535.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosourea Compounds; 869-01-2 / N-nitrosobutylurea
  •  go-up   go-down


62. Karnowski A, Cao C, Matthias G, Carotta S, Corcoran LM, Martensson IL, Skok JA, Matthias P: Silencing and nuclear repositioning of the lambda5 gene locus at the pre-B cell stage requires Aiolos and OBF-1. PLoS One; 2008;3(10):e3568
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing and nuclear repositioning of the lambda5 gene locus at the pre-B cell stage requires Aiolos and OBF-1.
  • The chromatin regulator Aiolos and the transcriptional coactivator OBF-1 have been implicated in regulating aspects of B cell maturation and activation.
  • Mice lacking either of these factors have a largely normal early B cell development.
  • However, when both factors are eliminated simultaneously a block is uncovered at the transition between pre-B and immature B cells, indicating that these proteins exert a critical function in developing B lymphocytes.
  • In mice deficient for Aiolos and OBF-1, the numbers of immature B cells are reduced, small pre-BII cells are increased and a significant impairment in immunoglobulin light chain DNA rearrangement is observed.
  • We identified genes whose expression is deregulated in the pre-B cell compartment of these mice.
  • In particular, we found that components of the pre-BCR, such as the surrogate light chain genes lambda5 and VpreB, fail to be efficiently silenced in double-mutant mice.
  • Strikingly, developmentally regulated nuclear repositioning of the lambda5 gene is impaired in pre-B cells lacking OBF-1 and Aiolos.
  • These studies uncover a novel role for OBF-1 and Aiolos in controlling the transcription and nuclear organization of genes involved in pre-BCR function.
  • [MeSH-major] Gene Order / physiology. Gene Rearrangement, B-Lymphocyte, Light Chain. Gene Silencing / immunology. Immunoglobulin lambda-Chains / genetics. Precursor Cells, B-Lymphoid / metabolism. Trans-Activators / physiology
  • [MeSH-minor] Animals. Bone Marrow Cells / metabolism. Bone Marrow Cells / physiology. Cell Differentiation / genetics. Cell Differentiation / immunology. Cell Nucleus / genetics. Cells, Cultured. Gene Expression Profiling. Gene Expression Regulation / immunology. Mice. Mice, Inbred C57BL. Mice, Knockout. Oligonucleotide Array Sequence Analysis

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1703-8 [12832394.001]
  • [Cites] Bioinformatics. 2003 Jul 22;19(11):1439-40 [12874059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8868-73 [12857960.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62 [14706621.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1577-83 [15004244.001]
  • [Cites] Annu Rev Immunol. 2004;22:55-79 [15032574.001]
  • [Cites] Trends Immunol. 2004 May;25(5):249-56 [15099565.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4265-71 [15383554.001]
  • [Cites] Genes Dev. 2000 Sep 1;14(17):2146-60 [10970879.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1745-50 [11172022.001]
  • [Cites] Immunity. 2001 May;14(5):603-15 [11371362.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2812-22 [11387214.001]
  • [Cites] Eur J Immunol. 2001 Jul;31(7):2164-9 [11449370.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):848-54 [11526401.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19272-8 [8702609.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):538-42 [8849727.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):542-7 [8849728.001]
  • [Cites] EMBO J. 1997 Apr 15;16(8):2004-13 [9155026.001]
  • [Cites] Immunity. 1997 Jul;7(1):25-36 [9252117.001]
  • [Cites] Cell. 1997 Dec 12;91(6):845-54 [9413993.001]
  • [Cites] Curr Opin Immunol. 1997 Apr;9(2):222-7 [9099800.001]
  • [Cites] J Immunol. 1998 Aug 1;161(3):1132-9 [9686571.001]
  • [Cites] Immunity. 1998 Oct;9(4):543-53 [9806640.001]
  • [Cites] Eur J Immunol. 1998 Nov;28(11):3738-48 [9842916.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):207-17 [10078203.001]
  • [Cites] Immunity. 1999 Mar;10(3):345-55 [10204490.001]
  • [Cites] EMBO J. 1999 Jun 1;18(11):3090-100 [10357820.001]
  • [Cites] Curr Top Microbiol Immunol. 1999;246:3-9; discussion 9-10 [10396033.001]
  • [Cites] J Exp Med. 1999 Jul 5;190(1):75-89 [10429672.001]
  • [Cites] Immunity. 1999 Jul;11(1):21-31 [10435576.001]
  • [Cites] Nat Immunol. 2005 Jan;6(1):31-41 [15580273.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(5):1804-20 [15713636.001]
  • [Cites] Semin Immunol. 2005 Apr;17(2):121-7 [15737573.001]
  • [Cites] Mol Immunol. 2005 May;42(7):749-61 [15829263.001]
  • [Cites] J Exp Med. 2005 May 2;201(9):1385-96 [15867091.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):497-508 [15928681.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7845-52 [15944289.001]
  • [Cites] Nat Rev Immunol. 2005 Jul;5(7):578-84 [15999097.001]
  • [Cites] Nat Immunol. 2005 Aug;6(8):836-43 [16025120.001]
  • [Cites] Nucleic Acids Res. 2005;33(14):4618-25 [16103132.001]
  • [Cites] EMBO J. 2005 Nov 16;24(22):3895-905 [16281060.001]
  • [Cites] Int Immunol. 2006 Jan;18(1):163-72 [16361315.001]
  • [Cites] Nucleic Acids Res. 2006;34(6):1807-15 [16582106.001]
  • [Cites] Genes Dev. 2006 Apr 15;20(8):933-8 [16618805.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11665-70 [16861304.001]
  • [Cites] Immunity. 2007 Mar;26(3):335-44 [17363301.001]
  • [Cites] Immunity. 2007 Sep;27(3):468-80 [17869135.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):4996-5005 [17911584.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1396-403 [17971486.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):5689-96 [11698441.001]
  • [Cites] J Immunol. 2001 Dec 15;167(12):6834-40 [11739500.001]
  • [Cites] Genome Res. 2002 Jan;12(1):98-111 [11779835.001]
  • [Cites] Bioinformatics. 2002 Feb;18(2):333-4 [11847087.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2695-703 [11884435.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 7;294(2):347-53 [12051718.001]
  • [Cites] Eur J Immunol. 2002 Sep;32(9):2481-9 [12207332.001]
  • [Cites] Cell. 2002 Sep 6;110(5):575-85 [12230975.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4007-17 [15372077.001]
  • [Cites] Cell. 1989 Sep 8;58(5):1001-7 [2505932.001]
  • [Cites] Mol Cell Biol. 1994 Nov;14(11):7633-42 [7935477.001]
  • [Cites] Cell. 1995 Feb 10;80(3):497-506 [7859290.001]
  • [Cites] Cell. 1995 Apr 7;81(1):41-51 [7720072.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4115-24 [7623806.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2781-90 [8654375.001]
  • [Cites] J Biol Chem. 1996 Jun 14;271(24):13927-30 [8663230.001]
  • [Cites] Immunity. 1999 Nov;11(5):547-54 [10591180.001]
  • [Cites] J Immunol. 2000 Jan 1;164(1):18-22 [10604987.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):23-32 [10620602.001]
  • [Cites] Mol Cell Biol. 2002 Dec;22(23):8320-31 [12417733.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):38-43 [12436112.001]
  • [Cites] J Immunol. 2003 Feb 1;170(3):1354-61 [12538695.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):1699-706 [12574333.001]
  • (PMID = 18974788.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM086852; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ikzf3 protein, mouse; 0 / Immunoglobulin lambda-Chains; 0 / Pou2af1 protein, mouse; 0 / Trans-Activators
  • [Other-IDs] NLM/ PMC2571989
  •  go-up   go-down


63. Keenan RA, De Riva A, Corleis B, Hepburn L, Licence S, Winkler TH, Mårtensson IL: Censoring of autoreactive B cell development by the pre-B cell receptor. Science; 2008 Aug 1;321(5889):696-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Censoring of autoreactive B cell development by the pre-B cell receptor.
  • We report here a role for the pre-B cell receptor, composed of Ig heavy and surrogate light chains, in the negative selection of cells expressing Ig heavy chains with the potential to generate autoantibodies.
  • Surrogate light-chain-deficient (SLC-/-) mice harbored elevated levels of antinuclear antibodies (ANAs) in their serum and showed evidence of escape of pre-B cells expressing prototypic autoantibody heavy chains from negative selection, leading to mature autoantibody secreting CD21-CD23- B cells in the periphery.
  • Thus, the pre-B cell receptor appears to censor the development of certain autoantibody-secreting cells and may represent an important factor in multifactorial autoimmune diseases.
  • [MeSH-major] Autoantibodies / blood. Autoimmunity. B-Lymphocytes / immunology. Pre-B Cell Receptors / immunology. Precursor Cells, B-Lymphoid / immunology. Self Tolerance
  • [MeSH-minor] Animals. Antibodies, Antinuclear / biosynthesis. Antibodies, Antinuclear / blood. B-Lymphocyte Subsets / immunology. Complementarity Determining Regions / genetics. Complementarity Determining Regions / immunology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / immunology. Immunoglobulin Light Chains, Surrogate / genetics. Immunoglobulin Light Chains, Surrogate / immunology. Lymphopoiesis. Mice. Spleen / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18566249.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Autoantibodies; 0 / Complementarity Determining Regions; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains, Surrogate; 0 / Pre-B Cell Receptors
  •  go-up   go-down


64. Melchers F: B cell development and its deregulation to transformed states at the pre-B cell receptor-expressing pre-BII cell stage. Curr Top Microbiol Immunol; 2005;294:1-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell development and its deregulation to transformed states at the pre-B cell receptor-expressing pre-BII cell stage.
  • This chapter will review the scenario of normal B cell development--from the decision of a lymphoid progenitor to enter the B-lineage, over the stages of the generation of the repertoires of antigen-receptor (immunoglobulin)-expressing cells, to the response of mature B cells to develop memory and plasma cells--highlighting some of the cellular stages and the molecular mechanisms that can generate and select transformed states of cells.
  • The scenarios for pre-B lymphoma (lymphocytic leukaemia) development are discussed in more detail.
  • [MeSH-major] B-Lymphocytes / cytology. B-Lymphocytes / immunology. Receptors, Antigen, B-Cell / metabolism
  • [MeSH-minor] Animals. Apoptosis. B-Cell-Specific Activator Protein / metabolism. Cell Differentiation. Cell Proliferation. Cell Transformation, Neoplastic. Gene Rearrangement, B-Lymphocyte. Humans. Interleukin-7 / metabolism. Lymphoma, B-Cell / etiology. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / immunology. Mice. Mutation. Receptors, Interleukin-7 / metabolism. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323425.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Interleukin-7; 0 / Pax5 protein, mouse; 0 / Receptors, Antigen, B-Cell; 0 / Receptors, Interleukin-7
  • [Number-of-references] 40
  •  go-up   go-down


65. Vettermann C, Jäck HM: The pre-B cell receptor: turning autoreactivity into self-defense. Trends Immunol; 2010 May;31(5):176-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pre-B cell receptor: turning autoreactivity into self-defense.
  • These cells then assemble microHCs with surrogate light chains (SLC) into a pre-B cell receptor (pre-BCR).
  • We propose that the pre-BCR has evolved from an ancient autoreactive BCR, since the SLC is an autoreactive entity that binds to the pre-BCR itself and to other self-antigens.
  • Abrogation of autoreactivity in the SLC diminishes pre-BCR signaling and impairs the clonal expansion of pre-B cells producing functional microHCs.
  • Since SLC expression is restricted to pre-B cells, the autoreactivity encoded by the pre-BCR can be utilized to pre-select the antibody repertoire, while simultaneously avoiding the formation of autoreactive B lymphocytes.
  • [MeSH-major] Autoimmunity. Pre-B Cell Receptors / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20356792.001).
  • [ISSN] 1471-4981
  • [Journal-full-title] Trends in immunology
  • [ISO-abbreviation] Trends Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Pre-B Cell Receptors
  •  go-up   go-down


66. Clark MR, Cooper AB, Wang LD, Aifantis I: The pre-B cell receptor in B cell development: recent advances, persistent questions and conserved mechanisms. Curr Top Microbiol Immunol; 2005;290:87-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pre-B cell receptor in B cell development: recent advances, persistent questions and conserved mechanisms.
  • B cell development is a process tightly regulated by the orchestrated signaling of cytokine receptors, the pre-B cell receptor (BCR) and the B cell receptor (BCR).
  • It commences with common lymphoid progenitors (CLP) up-regulating the expression of B cell-related genes and committing to the B cell lineage.
  • Cytokine signaling (IL-7, stem cell factor, FLT3-L) is essential at this stage of development as it suppresses cell death, sustains proliferation and facilitates heavy chain rearrangements.
  • As a result of heavy chain recombination, the pre-BCR is expressed, which then becomes the primary determiner of survival, cell cycle entry and allelic exclusion.
  • In this review, we discuss the mechanisms of B cell lineage commitment and describe the signaling pathways that are initiated by the pre-BCR.
  • Finally, we compare pre-BCR and pre-TCR structure, signal transduction and function, drawing parallels between early pre-B and pre-T cell development.
  • [MeSH-minor] Animals. Cell Differentiation. Cell Lineage. Gene Expression Regulation. Humans. Mice. Pre-B Cell Receptors. Receptors, Antigen, B-Cell. Signal Transduction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480040.001).
  • [ISSN] 0070-217X
  • [Journal-full-title] Current topics in microbiology and immunology
  • [ISO-abbreviation] Curr. Top. Microbiol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Pre-B Cell Receptors; 0 / Receptors, Antigen, B-Cell
  • [Number-of-references] 90
  •  go-up   go-down


67. Espeli M, Rossi B, Mancini SJ, Roche P, Gauthier L, Schiff C: Initiation of pre-B cell receptor signaling: common and distinctive features in human and mouse. Semin Immunol; 2006 Feb;18(1):56-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initiation of pre-B cell receptor signaling: common and distinctive features in human and mouse.
  • B cell development in the bone marrow is a highly regulated process and expression of a functional pre-BCR represents a crucial checkpoint, common to human and mouse.
  • In this review, we discuss pre-BCR analogies and differences between the two species leading to pre-B cell differentiation and proliferation.
  • In addition, the mechanisms triggering pre-BCR activation are reviewed, taking into account the recent report of heparan sulfates and galectin 1 as stromal cell-derived pre-BCR ligands.
  • Finally, ligand-induced pre-BCR activation models are proposed on the bases of the differences reported for pre-BCR and IL7 dependencies in the two species.
  • [MeSH-major] B-Lymphocytes / metabolism. Cell Differentiation / physiology. Membrane Glycoproteins / physiology. Signal Transduction / physiology
  • [MeSH-minor] Amino Acid Sequence. Animals. Humans. Mice. Molecular Sequence Data. Pre-B Cell Receptors. Receptors, Antigen, B-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337808.001).
  • [ISSN] 1044-5323
  • [Journal-full-title] Seminars in immunology
  • [ISO-abbreviation] Semin. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Glycoproteins; 0 / Pre-B Cell Receptors; 0 / Receptors, Antigen, B-Cell
  • [Number-of-references] 102
  •  go-up   go-down


68. Rossi B, Espeli M, Schiff C, Gauthier L: Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation. J Immunol; 2006 Jul 15;177(2):796-803
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clustering of pre-B cell integrins induces galectin-1-dependent pre-B cell receptor relocalization and activation.
  • Interactions between B cell progenitors and bone marrow stromal cells are essential for normal B cell differentiation.
  • We have previously shown that an immune developmental synapse is formed between human pre-B and stromal cells in vitro, leading to the initiation of signal transduction from the pre-BCR.
  • This process relies on the direct interaction between the pre-BCR and the stromal cell-derived galectin-1 (GAL1) and is dependent on GAL1 anchoring to cell surface glycosylated counterreceptors, present on stromal and pre-B cells.
  • Pre-B cell integrins and their stromal cell ligands (ADAM15/fibronectin), together with the pre-BCR and GAL1, form a homogeneous lattice at the contact area between pre-B and stromal cells.
  • Moreover, integrin and pre-BCR relocalizations into the synapse are synchronized and require actin polymerization.
  • Finally, cross-linking of pre-B cell integrins in the presence of GAL1 is sufficient for driving pre-BCR recruitment into the synapse, leading to the initiation of pre-BCR signaling.
  • These results suggest that during pre-B/stromal cell synapse formation, relocalization of pre-B cell integrins mediated by their stromal cell ligands drives pre-BCR clustering and activation, in a GAL1-dependent manner.
  • [MeSH-major] B-Lymphocytes / metabolism. Cell Aggregation. Galectin 1 / physiology. Hematopoietic Stem Cells / metabolism. Integrins / metabolism. Membrane Glycoproteins / metabolism. Receptor Aggregation
  • [MeSH-minor] Actins / metabolism. Antibodies, Monoclonal / metabolism. Cell Communication / immunology. Cell Line, Tumor. Coculture Techniques. Cross-Linking Reagents / metabolism. Humans. Ligands. Pre-B Cell Receptors. Receptors, Antigen, B-Cell. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818733.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Cross-Linking Reagents; 0 / Galectin 1; 0 / Integrins; 0 / Ligands; 0 / Membrane Glycoproteins; 0 / Pre-B Cell Receptors; 0 / Receptors, Antigen, B-Cell
  •  go-up   go-down


69. Herzog S, Storch B, Jumaa H: Dual role of the adaptor protein SLP-65: organizer of signal transduction and tumor suppressor of pre-B cell leukemia. Immunol Res; 2006;34(2):143-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual role of the adaptor protein SLP-65: organizer of signal transduction and tumor suppressor of pre-B cell leukemia.
  • B cell development is characterized by a coordinated progression through defined stages that are controlled at several checkpoints.
  • Signals from the pre-B cell receptor (pre-BCR) are essential for regulated transition from the pre-B cell stage.
  • Recent findings indicate an additional function of SLP-65 as a tumor suppressor that regulates pre-B cell proliferation.
  • We will discuss here the potential mechanisms by which SLP-65 controls the pre-B cell checkpoint.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. B-Lymphocytes / cytology. Carrier Proteins / physiology. Phosphoproteins / physiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Signal Transduction. Tumor Suppressor Proteins / physiology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Humans. Membrane Glycoproteins / metabolism. Pre-B Cell Receptors. Protein-Tyrosine Kinases. Receptors, Antigen, B-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1999 Nov;11(5):547-54 [10591180.001]
  • [Cites] Immunity. 2002 Oct;17 (4):473-85 [12387741.001]
  • [Cites] Nature. 1995 Nov 16;378(6554):298-302 [7477352.001]
  • [Cites] Cell. 1996 May 31;85(5):707-20 [8646779.001]
  • [Cites] Eur J Immunol. 2001 Jul;31(7):2164-9 [11449370.001]
  • [Cites] Nature. 1990 Jan 25;343(6256):377-81 [1689011.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):865-72 [12097390.001]
  • [Cites] J Immunol. 1993 Jan 15;150(2):377-86 [8419471.001]
  • [Cites] J Biol Chem. 1999 May 14;274(20):13886-93 [10318797.001]
  • [Cites] Nature. 1991 Apr 4;350(6317):423-6 [1901381.001]
  • [Cites] Nat Immunol. 2003 Feb;4(2):117-23 [12514734.001]
  • [Cites] EMBO J. 1998 Apr 1;17 (7):1973-85 [9524120.001]
  • [Cites] Nature. 2003 May 22;423(6938):452-6 [12761551.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):41423-7 [12205088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98 (5):2582-6 [11226282.001]
  • [Cites] Oncogene. 2004 Feb 5;23 (5):1064-75 [14676846.001]
  • [Cites] EMBO J. 2002 Dec 2;21(23):6461-72 [12456653.001]
  • [Cites] J Exp Med. 2000 Sep 18;192(6):847-56 [10993915.001]
  • [Cites] J Exp Med. 1998 Oct 5;188(7):1297-306 [9763609.001]
  • [Cites] Immunity. 2003 Nov;19(5):669-78 [14614854.001]
  • [Cites] Nature. 1990 Feb 22;343(6260):760-2 [2304550.001]
  • [Cites] Cell. 1992 May 29;69(5):823-31 [1591779.001]
  • [Cites] Science. 1995 Aug 4;269(5224):682-5 [7624798.001]
  • [Cites] J Exp Med. 2003 Jul 7;198(1):91-8 [12835482.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13014-9 [12271131.001]
  • [Cites] Immunity. 2003 Jun;18(6):777-87 [12818159.001]
  • [Cites] J Exp Med. 1998 Oct 5;188(7):1287-95 [9763608.001]
  • [Cites] Nat Immunol. 2001 Jul;2(7):625-31 [11429547.001]
  • [Cites] Science. 1996 Apr 19;272(5260):411-4 [8602530.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6403-11 [11714806.001]
  • [Cites] Nat Cell Biol. 1999 Aug;1(4):193-9 [10559916.001]
  • [Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):23-32 [10620602.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1549-60 [10587346.001]
  • [Cites] Immunity. 2000 Jul;13(1):25-35 [10933392.001]
  • [Cites] J Mol Biol. 1998 Aug 21;281(3):523-37 [9698567.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):171-82 [10899904.001]
  • [Cites] Curr Biol. 1999 Jun 17;9(12 ):661-4 [10375532.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1617-26 [12486104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2755-60 [10688901.001]
  • [Cites] Immunity. 2003 Aug;19(2):295-305 [12932362.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1815-23 [7500027.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5988-96 [14634110.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2442-51 [8665852.001]
  • [Cites] Immunity. 1999 Dec;11(6):771-81 [10626899.001]
  • [Cites] Nat Cell Biol. 1999 Aug;1(4):207-14 [10559918.001]
  • [Cites] Int Immunol. 2000 Mar;12(3):397-404 [10700474.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):38-43 [12436112.001]
  • [Cites] Adv Immunol. 1996;63:1-41 [8787628.001]
  • [Cites] J Exp Med. 2001 Aug 6;194(3):275-84 [11489947.001]
  • [Cites] Immunity. 1999 Jan;10 (1):117-25 [10023776.001]
  • [Cites] EMBO J. 1998 Apr 1;17 (7):1961-72 [9524119.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):791-5 [9705962.001]
  • [Cites] J Exp Med. 2001 Feb 19;193(4):435-45 [11181696.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1583-96 [11733573.001]
  • [Cites] Cell. 1993 Jul 16;74(1):205-14 [8334704.001]
  • [Cites] Blood. 1998 Feb 1;91(3):940-8 [9446655.001]
  • [Cites] Immunity. 2000 Aug;13(2):243-53 [10981967.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24945-52 [10823839.001]
  • [Cites] Immunity. 1995 Sep;3(3):283-99 [7552994.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3969-78 [11494125.001]
  • [Cites] Int Immunol. 1999 Mar;11(3):453-60 [10221657.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2239-43 [10051625.001]
  • [Cites] Nature. 2001 Sep 20;413(6853):323-7 [11565035.001]
  • [Cites] Mol Cell. 2002 Nov;10 (5):1057-69 [12453414.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2733-7 [8146183.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20055-63 [11274146.001]
  • [Cites] Mol Cell. 2005 Jun 10;18(6):699-709 [15949444.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1949-54 [10583957.001]
  • [Cites] Immunity. 1996 Dec;5(6):575-89 [8986717.001]
  • [Cites] EMBO J. 1991 Feb;10(2):327-36 [1991449.001]
  • (PMID = 16760574.001).
  • [ISSN] 0257-277X
  • [Journal-full-title] Immunologic research
  • [ISO-abbreviation] Immunol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / Carrier Proteins; 0 / Membrane Glycoproteins; 0 / Phosphoproteins; 0 / Pre-B Cell Receptors; 0 / Receptors, Antigen, B-Cell; 0 / Tumor Suppressor Proteins; EC 2.7.10.1 / Agammaglobulinaemia tyrosine kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 71
  •  go-up   go-down


70. Schuh W, Meister S, Herrmann K, Bradl H, Jäck HM: Transcriptome analysis in primary B lymphoid precursors following induction of the pre-B cell receptor. Mol Immunol; 2008 Jan;45(2):362-75
Hazardous Substances Data Bank. TETRACYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analysis in primary B lymphoid precursors following induction of the pre-B cell receptor.
  • Pre-BCR signals are part of a checkpoint where early precursor (pre-) B cells with a pairing Ig muH chain (muHC) are clonally expanded before they differentiate into IgL-rearranging, resting pre-B cells.
  • A pre-BCR consists of two muHCs, two surrogate L chains and the signal transducer Igalpha/Igbeta.
  • The molecular circuits by which the pre-BCR controls proliferation and differentiation of pre-B cells are poorly characterized.
  • Therefore, we identified the differential transcriptome by genome-wide expression profiling in progenitor (pro-) B cells from a Rag2-deficient mouse, in which the expression of a transgenic muHC and thus a pre-BCR as well as pre-BCR-mediated clonal expansion can be controlled by tetracycline (muHC-inducible mouse).
  • This analysis revealed that pre-BCR signals upregulate components of the BCR signalosome, open the IgL chain (LC) locus and induce the krüppel-like transcription factor KLF2, a key regulator of quiescence and lymphocyte migration.
  • Hence, pre-BCR signals establish the molecular network for BCR signaling even before the production of an IgLC and induce the expression of KLF2, a candidate for controlling clonal expansion and migration of functional pre-B cells.
  • [MeSH-major] B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Gene Expression Regulation. Pre-B Cell Receptors / genetics. Stem Cells / immunology. Stem Cells / metabolism. Transcription, Genetic


71. Stanciu-Herrera C, Morgan C, Herrera L: Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines. Leuk Res; 2008 Apr;32(4):625-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines.
  • The monoclonal antibodies (MAbs) HD37 and RFB4 bind to receptors on precursor B acute lymphoblastic leukemia (ALL) cells.
  • HD37 and not RFB4 increased the in vitro cytotoxicity of daunorubicin (DNR) and vincristine (VCR) in three Pre-B ALL cell lines.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):380-9 [11888077.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):669-82 [14551500.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Nov;56(1):30-42 [14582135.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1274-81 [14977825.001]
  • [Cites] Exp Cell Res. 2004 Aug 15;298(2):560-73 [15265702.001]
  • [Cites] J Immunol. 1987 May 1;138(9):2793-9 [2437199.001]
  • [Cites] Leuk Res. 1988;12(2):135-41 [3282129.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4906-12 [2667754.001]
  • [Cites] J Immunol. 1991 Dec 1;147(11):3663-71 [1719083.001]
  • [Cites] Crit Rev Oncol Hematol. 1991 Dec;11(4):267-97 [1777090.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2315-20 [1384801.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2624-33 [8219217.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1329-36 [7509655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4048-52 [7513431.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):14-22 [8204688.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3096-104 [7534787.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3457-65 [7780133.001]
  • [Cites] Leuk Lymphoma. 1995 Aug;18(5-6):385-97 [8528044.001]
  • [Cites] Curr Biol. 1997 Feb 1;7(2):133-43 [9016707.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7509-14 [9207122.001]
  • [Cites] Leuk Res. 1998 Jul;22(7):567-79 [9680106.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):3176-85 [9743386.001]
  • [Cites] Exp Hematol. 2005 Feb;33(2):199-211 [15676214.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):694-704 [15681517.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3676-85 [15738535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15178-83 [16217038.001]
  • [Cites] Leukemia. 2003 Feb;17(2):334-8 [12592332.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):3920-7 [10632321.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1302-13 [10778955.001]
  • [Cites] Immunity. 2000 Jul;13(1):47-57 [10933394.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):800-9 [11564066.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):44315-22 [11551923.001]
  • [CommentIn] Leuk Res. 2008 Jun;32(6):847-9 [18191203.001]
  • (PMID = 17706771.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101897-04; United States / NCI NIH HHS / CA / K01 CA101897-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD19; 0 / Antineoplastic Agents, Phytogenic; 0 / Sialic Acid Binding Ig-like Lectin 2; 5J49Q6B70F / Vincristine; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS42262; NLM/ PMC2276361
  •  go-up   go-down


72. van Loo PF, Dingjan GM, Maas A, Hendriks RW: Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling. Immunity; 2007 Sep;27(3):468-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling.
  • The pre-B cell receptor (pre-BCR), composed of immunoglobulin mu heavy chain and the surrogate light chain (SLC) proteins lambda5 and Vpreb, signals for proliferation and maturation of developing pre-B cells.
  • It has been assumed that pre-B cells stop cycling by the pre-BCR-mediated downregulation of SLC transcription.
  • We generated transgenic mice expressing SLC throughout B cell development and, remarkably, found that enforced SLC expression had no effect on pre-B cell proliferation or differentiation.
  • However, in the presence of conventional immunoglobulin light chains, SLC components had the capacity to induce constitutive BCR internalization, secondary immunoglobulin light-chain rearrangement, and a severe developmental arrest of immature B cells, dependent on the adaptor protein Slp65.
  • Thus, the silencing of SLC genes is not essential for the limitation of pre-B cell proliferation, but is required for the prevention of constitutive activation of B cells.
  • [MeSH-major] B-Lymphocytes / immunology. Cell Differentiation / immunology. Gene Silencing. Hematopoietic Stem Cells / immunology. Immunoglobulin Light Chains / genetics. Immunoglobulin Light Chains / immunology. Membrane Glycoproteins / genetics. Membrane Glycoproteins / immunology
  • [MeSH-minor] Animals. Cell Proliferation. Flow Cytometry. Gene Rearrangement, B-Lymphocyte, Light Chain / immunology. Immunoglobulin Light Chains, Surrogate. Lymphocyte Activation / immunology. Mice. Mice, Transgenic. Signal Transduction / immunology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869135.001).
  • [ISSN] 1074-7613
  • [Journal-full-title] Immunity
  • [ISO-abbreviation] Immunity
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Light Chains, Surrogate; 0 / Membrane Glycoproteins
  •  go-up   go-down


73. Kim JY, Park SK, Kim HG, Cho SJ, Kim J, Kang CJ: The HSS3/4 enhancer of Crlz1-IgJ locus is another target of EBF in the pre-B cell stage of B cell development. Immunol Lett; 2006 Sep 15;107(1):63-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HSS3/4 enhancer of Crlz1-IgJ locus is another target of EBF in the pre-B cell stage of B cell development.
  • Unexpectedly, the HSS3/4 enhancer was also found to be opened in the pre-B cells.
  • However, this opening of HSS3/4 enhancer in the pre-B cells could not be related to the IgJ gene expression, because neither the IgJ promoter was opened nor its gene was expressed at the pre-B cell stage of B cell development.
  • Instead, it was postulated that the opened HSS3/4 enhancer might act on some other nearby promoter in pre-B cells, which is now guessed to be the Crlz1 promoter located at 22.5 kb from it.
  • In consistence with this pre-B cell-specific opening of the HSS3/4 enhancer, a pre-B cell-specific in vivo footprint on a sequence similar to the EBF-binding consensus was detected within the enhancer.
  • In this paper, we show that the protein causing the pre-B cell-specific in vivo footprint on a sequence similar to the EBF-binding consensus is truly EBF as judged by EMSA using various oligo-DNA competitors and anti-EBF antibodies.
  • Also, as expected from other previous reports, EBF was shown to be expressed highly in pre-B cells, but very little or not in immature B, mature B and plasma cells using both the cell lines and FACS-sorted normal primary cells.
  • Convincingly, mutations within the EBF site of HSS3/4 enhancer were shown to significantly impair the HSS3/4 enhancer activity in the pre-B cells, but not in the plasma cells.
  • [MeSH-major] B-Lymphocytes / cytology. Cell Differentiation / physiology. DNA-Binding Proteins / genetics. Enhancer Elements, Genetic / genetics. Nerve Tissue Proteins / genetics. Promoter Regions, Genetic / genetics. Trans-Activators / genetics. Transcription Factors / genetics
  • [MeSH-minor] Animals. Base Sequence. Blotting, Western. Cell Line. Electrophoretic Mobility Shift Assay. Flow Cytometry. Immunoglobulin J-Chains / genetics. Immunoglobulin J-Chains / immunology. Mice. Molecular Sequence Data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962668.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Crlz1protein, mouse; 0 / DNA-Binding Proteins; 0 / Ebf1 protein, mouse; 0 / Immunoglobulin J-Chains; 0 / Nerve Tissue Proteins; 0 / Trans-Activators; 0 / Transcription Factors
  •  go-up   go-down


74. Wossning T, Herzog S, Köhler F, Meixlsperger S, Kulathu Y, Mittler G, Abe A, Fuchs U, Borkhardt A, Jumaa H: Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med; 2006 Dec 25;203(13):2829-40
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
  • The nonreceptor protein spleen tyrosine kinase (Syk) is a key mediator of signal transduction in a variety of cell types, including B lymphocytes.
  • We show that deregulated Syk activity allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are then able to induce leukemia in mice.
  • Syk-transformed pre-B cells show a characteristic pattern of tyrosine phosphorylation, increased c-Myc expression, and defective differentiation.
  • Treatment of Syk-transformed pre-B cells with a novel Syk-specific inhibitor (R406) reduces tyrosine phosphorylation and c-Myc expression.
  • In addition, R406 treatment removes the developmental block and allows the differentiation of the Syk-transformed pre-B cells into immature B cells.
  • Because R406 treatment also prevents the proliferation of c-Myc-transformed pre-B cells, our data indicate that endogenous Syk kinase activity may be required for the survival of pre-B cells transformed by other oncogenes.
  • Collectively, our data suggest that Syk is a protooncogene involved in the transformation of lymphocytes, thus making Syk a potential target for the treatment of leukemia.
  • [MeSH-major] B-Lymphocytes / metabolism. Cell Differentiation / physiology. Intracellular Signaling Peptides and Proteins / metabolism. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adaptor Proteins, Signal Transducing / metabolism. Adoptive Transfer. Animals. Benzamides. Cell Line. Cell Proliferation / drug effects. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Fusion Proteins, bcr-abl / antagonists & inhibitors. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / metabolism. Humans. Imatinib Mesylate. Intercellular Signaling Peptides and Proteins / pharmacology. Intercellular Signaling Peptides and Proteins / physiology. Leukemia / genetics. Leukemia / pathology. Leukemia / therapy. Mice. Mice, Inbred BALB C. Mice, Knockout. Oxazines / pharmacology. Phospholipase C gamma / genetics. Phospholipase C gamma / metabolism. Phosphorylation / drug effects. Piperazines / pharmacology. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-myc / genetics. Proto-Oncogene Proteins c-myc / metabolism. Pyridines / pharmacology. Pyrimidines / pharmacology. Receptors, Antigen, B-Cell / genetics. Spleen / drug effects. Spleen / metabolism. Spleen / pathology. Transfection

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2005 Jun;124(6):1293-9 [15955106.001]
  • [Cites] Haematologica. 2005 Jul;90(7):899-905 [15996927.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Jan 1;173(1):56-63 [16192454.001]
  • [Cites] Blood. 2006 Jan 1;107(1):197-204 [16160012.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):303-16 [16409295.001]
  • [Cites] Leukemia. 2006 Feb;20(2):313-8 [16341044.001]
  • [Cites] Nat Rev Immunol. 2006 Jan;6(1):67-78 [16493428.001]
  • [Cites] J Pharmacol Exp Ther. 2006 May;317(2):571-8 [16452391.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2748-57 [16369490.001]
  • [Cites] Cell. 2006 May 19;125(4):761-74 [16713566.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3428-33 [16888096.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008 [16946104.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32662-6 [10551821.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):23-32 [10620602.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):742-7 [10963601.001]
  • [Cites] Immunol Rev. 2000 Aug;176:30-46 [11043766.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1050-5 [11159536.001]
  • [Cites] J Biochem. 2001 Aug;130(2):177-86 [11481033.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3969-78 [11494125.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7085-95 [11742985.001]
  • [Cites] Gene Ther. 2002 Apr;9(8):477-87 [11948372.001]
  • [Cites] J Cell Mol Med. 2002 Apr-Jun;6(2):151-9 [12169201.001]
  • [Cites] Semin Immunol. 2002 Oct;14(5):343-9 [12220935.001]
  • [Cites] Cancer Lett. 2003 Jan 10;189(1):97-102 [12445683.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):945-56 [12461567.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):38-43 [12436112.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1283-94 [12504005.001]
  • [Cites] Anal Chem. 2003 Feb 1;75(3):663-70 [12585499.001]
  • [Cites] Nat Immunol. 2003 Mar;4(3):274-9 [12563261.001]
  • [Cites] Ann Intern Med. 2003 May 20;138(10):819-30 [12755554.001]
  • [Cites] Nature. 2003 May 22;423(6938):452-6 [12761551.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1511-24 [12771181.001]
  • [Cites] Immunity. 2003 Jun;18(6):825-36 [12818163.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):849-56 [12897780.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3091-101 [12960335.001]
  • [Cites] Leukemia. 2004 Mar;18(3):548-55 [14749700.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1815-8 [15188513.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13417-22 [15347803.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7346-54 [15492255.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Cell. 1987 Jun 19;49(6):775-83 [3495343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Feb;86(4):1168-72 [2784003.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):973-6 [2117639.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Oncogene. 1991 Apr;6(4):653-7 [2030914.001]
  • [Cites] Cell. 1992 Sep 18;70(6):901-10 [1525828.001]
  • [Cites] EMBO J. 1994 Mar 15;13(6):1341-9 [8137818.001]
  • [Cites] Cell. 1994 Apr 8;77(1):133-43 [8156589.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1725-9 [7513017.001]
  • [Cites] Oncogene. 1995 Feb 16;10(4):705-11 [7862448.001]
  • [Cites] Mol Cell Biol. 1995 Jul;15(7):3571-8 [7791764.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):611-5 [7629518.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Aug 4;213(1):273-81 [7639745.001]
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):19141-50 [7642581.001]
  • [Cites] Nature. 1995 Nov 16;378(6554):298-302 [7477352.001]
  • [Cites] Nature. 1995 Nov 16;378(6554):303-6 [7477353.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):3187-94 [8621719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1919-24 [9050880.001]
  • [Cites] Mol Cell Biol. 1998 Aug;18(8):4872-82 [9671496.001]
  • [Cites] J Immunol. 1998 Nov 15;161(10):5276-83 [9820500.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2761-5 [10072522.001]
  • [Cites] Immunol Lett. 1999 May 3;68(1):89-93 [10397161.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):431-9 [15684322.001]
  • (PMID = 17130299.001).
  • [ISSN] 0022-1007
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / B cell linker protein; 0 / Benzamides; 0 / DNA-Binding Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; 0 / Oxazines; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-myc; 0 / Pyridines; 0 / Pyrimidines; 0 / Rag2 protein, mouse; 0 / Receptors, Antigen, B-Cell; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / Fusion Proteins, bcr-abl; EC 3.1.4.3 / Phospholipase C gamma
  • [Other-IDs] NLM/ PMC2118175
  •  go-up   go-down


75. Yuroff AS, Jefcoate CR, Czuprynski CJ: Close proximity, but not VLA-4-dependent adherence between pre-B cells and bone marrow stromal cells, is required for DMBA-induced apoptosis of pre-B cells in vitro. Toxicol Lett; 2005 Apr 10;156(2):253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Close proximity, but not VLA-4-dependent adherence between pre-B cells and bone marrow stromal cells, is required for DMBA-induced apoptosis of pre-B cells in vitro.
  • We have previously reported that 7,12-dimethylbenz[a]anthracene (DMBA) induced apoptosis in precursor B lymphocytes (pre-B cells) only when they were co-cultured with bone marrow stromal (BMS) cells.
  • The goal of this research was to determine whether this process was dependent on the adherence of the pre-B cells and stromal cells.
  • Conditioned media from DMBA-treated BMS cells induced apoptosis in pre-B cells, but only when the pre-B cells were co-cultured with stromal cells.
  • When the stromal cells and pre-B cells were separated with a membrane filter insert, DMBA-induced apoptosis of the pre-B cells was blocked suggesting that contact with or close proximity to stromal cells was required for apoptosis.
  • The addition of an anti-VLA-4 Mab disrupted adherence of pre-B cells to the stromal cell monolayer, but did not diminish the numbers of apoptotic pre-B cells.
  • The results of this study support the hypothesis stromal cells and pre-B cells must be in close proximity for apoptosis to occur, but direct interaction via VLA-4 and VCAM-1 is unlikely to be required for this response.
  • [MeSH-minor] Animals. Cell Adhesion. Cell Line. Environmental Pollutants / toxicity. Mice. Rats. Stromal Cells / physiology. Vascular Cell Adhesion Molecule-1 / physiology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737488.001).
  • [ISSN] 0378-4274
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA81493
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benz(a)Anthracenes; 0 / Environmental Pollutants; 0 / Integrin alpha4beta1; 0 / Vascular Cell Adhesion Molecule-1; 2564-65-0 / 7,12-dihydroxymethylbenz(a)anthracene
  •  go-up   go-down


76. Chiaretti S, Guarini A, De Propris MS, Tavolaro S, Intoppa S, Vitale A, Iacobelli S, Elia L, Ariola C, Ritz J, Foà R: ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood; 2006 Jan 1;107(1):197-204
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
  • We evaluated the expression of 2 members of the Syk family, ZAP-70 and Syk, in acute lymphoblastic leukemia (ALL) samples, using data derived from a series of 33 T-ALL and 95 B-lineage adult ALL patients analyzed by oligonucleotide arrays.
  • Of the B-lineage ALL cases, 37 were BCR/ABL+, 10 were ALL1/AF4+, 5 were E2A/PBX1+, and 43 carried no known molecular abnormality.
  • A higher ZAP-70 expression was also observed in the pre-B group (P < .001).
  • In ALL, ZAP-70 expression is associated with the E2A/PBX1 rearrangement and pre-B stage and may have a prognostic role and be a candidate molecule for targeted therapies.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adult. Cell Differentiation. Child. Enzyme Precursors / genetics. Follow-Up Studies. Gene Expression Profiling. Gene Rearrangement. Humans. Immunoglobulin mu-Chains. Intracellular Signaling Peptides and Proteins. Prognosis. Protein-Tyrosine Kinases / genetics. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160012.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Precursors; 0 / Homeodomain Proteins; 0 / Immunoglobulin mu-Chains; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


77. Storch B, Meixlsperger S, Jumaa H: The Ig-alpha ITAM is required for efficient differentiation but not proliferation of pre-B cells. Eur J Immunol; 2007 Jan;37(1):252-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ig-alpha ITAM is required for efficient differentiation but not proliferation of pre-B cells.
  • Signals from the pre-B cell receptor (pre-BCR) mediated by the cytoplasmic tails of Ig-alpha/Ig-beta are essential for developing B cells.
  • To analyze the role of Ig-alpha ITAM and non-ITAM tyrosines in pre-BCR signaling, we reconstituted individual tyrosine mutants of Ig-alpha in src homology 2 domain-containing leukocyte protein of 65 kDa (SLP-65)/Ig-alpha double-deficient pre-B cells.
  • We show that the Ig-alpha mutants led to comparable pre-BCR expression on the cell surface, while the pre-BCR-induced tyrosine phosphorylation was different.
  • We further show that the reconstitution of Ig-alpha and the resulting pre-BCR expression led to enrichment of the pre-BCR-expressing cells in vitro irrespective of the introduced Ig-alpha mutation.
  • Our results indicate that surface IL-7 receptor expression is modulated by the pre-BCR, thereby increasing the IL-7 sensitivity of the respective cells.
  • In contrast to the comparable pre-B cell proliferation, however, the Ig-alpha mutants differed in their capacity to induce calcium flux and activate efficient pre-B cell differentiation.
  • Together, our data suggest that ITAM tyrosines and Y204 are required for efficient pre-B cell differentiation but not proliferation.
  • [MeSH-major] Antigens, CD79 / physiology. B-Lymphocyte Subsets / cytology. Cell Differentiation / immunology. Cell Proliferation. Stem Cells / cytology. Stem Cells / immunology. Tyrosine
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / biosynthesis. Adaptor Proteins, Signal Transducing / genetics. Amino Acid Motifs / genetics. Animals. Cells, Cultured. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Membrane Glycoproteins / physiology. Mice. Mice, Inbred BALB C. Mutagenesis, Site-Directed. Phosphorylation. Pre-B Cell Receptors. Receptors, Antigen, B-Cell / biosynthesis. Receptors, Antigen, B-Cell / genetics. Receptors, Antigen, B-Cell / physiology. Signal Transduction / genetics. Signal Transduction / immunology


78. Herzog S, Jumaa H: The N terminus of the non-T cell activation linker (NTAL) confers inhibitory effects on pre-B cell differentiation. J Immunol; 2007 Feb 15;178(4):2336-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The N terminus of the non-T cell activation linker (NTAL) confers inhibitory effects on pre-B cell differentiation.
  • SLP-65 and the linker for activation of T cells (LAT) are central adaptor proteins that link the activated pre-BCR to downstream events in pre-B cells.
  • Recently, a new transmembrane adaptor called NTAL/LAB/LAT2 (hereafter called NTAL for non-T cell activation linker) with striking functional and structural similarity to LAT has been identified in B cells.
  • In this study, we compare the function of NTAL and LAT in pre-BCR signaling and show that, in contrast to LAT, NTAL does not induce pre-BCR down-regulation, calcium flux, or pre-B cell differentiation.
  • This insertion rendered NTAL capable of activating pre-BCR down-regulation and calcium flux.
  • Unexpectedly however, the ability of NTAL to induce calcium flux was not sufficient to promote pre-B cell differentiation, suggesting that the PLC-gamma binding motif has only partial effects on NTAL-mediated pre-BCR signaling.
  • By generating chimeric swap mutants, we identified the N terminus of NTAL as an inhibitory domain that prevents pre-B cell differentiation while allowing pre-BCR down-regulation and receptor-mediated calcium flux.
  • Our data suggest that, in addition to the missing PLC-gamma1/2 binding motif, the N terminus is responsible for the functional differences between NTAL and LAT in pre-B cells.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / immunology. Adaptor Proteins, Vesicular Transport / immunology. B-Lymphocytes / immunology. Calcium Signaling / immunology. Cell Differentiation / immunology. Membrane Proteins / immunology. Phosphoproteins / immunology. Proto-Oncogene Proteins c-bcr / immunology
  • [MeSH-minor] Amino Acid Motifs / genetics. Amino Acid Motifs / immunology. Animals. Down-Regulation / immunology. Mice. Mutation. Protein Binding / immunology. Type C Phospholipases / genetics. Type C Phospholipases / immunology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277139.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adaptor Proteins, Vesicular Transport; 0 / LAB protein, mouse; 0 / Lat protein, mouse; 0 / Membrane Proteins; 0 / Phosphoproteins; EC 2.7.11.1 / Bcr protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr; EC 3.1.4.- / Type C Phospholipases
  •  go-up   go-down


79. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD: TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2006 Oct 10;103(41):15166-71
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is a clonal disease that evolves through the accrual of genetic rearrangements and/or mutations within the dominant clone.
  • The TEL-AML1 (ETV6-RUNX1) fusion in precursor-B (pre-B) ALL is the most common genetic rearrangement in childhood cancer; however, the cellular origin and the molecular pathogenesis of TEL-AML1-induced leukemia have not been identified.
  • TEL-AML1 expression in all lineages, but not lymphoid-restricted expression, led to progenitor cell expansion that evolved into oligoclonal B-lineage ALL in 3% of the transgenic zebrafish.
  • This leukemia was transplantable to conditioned wild-type recipients.
  • We demonstrate that TEL-AML1 induces a B cell differentiation arrest, and that leukemia development is associated with loss of TEL expression and elevated Bcl2/Bax ratio.
  • The TEL-AML1 transgenic zebrafish models human pre-B ALL, identifies the molecular pathways associated with leukemia development, and serves as the foundation for subsequent genetic screens to identify modifiers and leukemia therapeutic targets.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] Gene. 2000 Mar 21;245(2):223-35 [10717473.001]
  • [Cites] Genesis. 2001 Apr;29(4):156-62 [11309848.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jun;31(2):134-42 [11319801.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):302-7 [11377288.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3437-42 [11423994.001]
  • [Cites] Blood. 2001 Aug 1;98(3):643-51 [11468162.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):731-7 [11584300.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Oct 15;130(2):93-104 [11675129.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7447-52 [11704876.001]
  • [Cites] Development. 2002 Apr;129(8):2015-30 [11934867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Blood. 2002 Jul 15;100(2):640-6 [12091359.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1285-92 [12094252.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3904-8 [12124316.001]
  • [Cites] Exp Hematol. 2002 Dec;30(12):1381-9 [12482499.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):155-64 [12526921.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):94-8 [12823350.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1238-46 [14608381.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 May 15;103(10):3890-6 [14726384.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8443-8 [15155899.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 17;322(2):623-30 [15325275.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1624-9 [15356660.001]
  • [Cites] J Exp Med. 1976 May 1;143(5):1265-70 [1083421.001]
  • [Cites] J Exp Med. 1991 May 1;173(5):1213-25 [1827140.001]
  • [Cites] Gene. 1994 Sep 30;147(2):223-6 [7926804.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 23;92(11):4917-21 [7761424.001]
  • [Cites] Blood. 1995 Oct 15;86(8):2876-91 [7579378.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4263-9 [7492786.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64 [8943060.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 15;89(20):1542-4 [9337352.001]
  • [Cites] Dev Biol. 1997 Dec 15;192(2):289-99 [9441668.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17525-30 [9651344.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1057-62 [10419898.001]
  • [Cites] J Natl Cancer Inst. 1965 Jan;34:117-30 [14287275.001]
  • [Cites] Exp Hematol. 2005 Feb;33(2):182-8 [15676212.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):127-32 [15681484.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6068-73 [15827121.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7579-91 [16044150.001]
  • [Cites] Blood. 2006 Jan 15;107(2):769-76 [16189266.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):187-90 [10712943.001]
  • (PMID = 17015828.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K22 CA120626; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TEL-AML1 fusion protein; 0 / bcl-2-Associated X Protein
  • [Other-IDs] NLM/ PMC1622794
  •  go-up   go-down


80. Tröger A, Siepermann M, Mahotka C, Wethkamp N, Bülle H, Laws HJ, Escherich G, Janka-Schaub G, Göbel U, Dilloo D: Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia. Klin Padiatr; 2007 May-Jun;219(3):127-33
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.
  • BACKGROUND: Survivin, a member of the inhibitor of apoptosis protein (IAP) family is transiently expressed at low levels during normal hematopoesis but profoundly overexpressed in adult leukemia potentially contributing to leukemogenesis due to deregulated apoptosis and defective cell cycle control.
  • PATIENTS AND METHODS: We therefore determined the expression of the functional survivin splice variants performing RT- and real-time PCR in a purely pediatric cohort of 20 patients suffering from precursor B-ALL (BCP-ALL).
  • RESULTS: Here, we demonstrate for the first time in pediatric patients with precursor B-ALL an association between lower survivin-2B expression and affiliation to the high risk group.
  • [MeSH-major] Apoptosis / genetics. Genetic Variation / genetics. Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Isoforms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525905.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Coumarins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 41806-51-3 / W10294A
  •  go-up   go-down


81. Welner R, Swett DJ, Pelsue SC: Age-related loss of bone marrow pre-B- and immature B-lymphocytes in the autoimmune-prone flaky skin mutant mice. Autoimmunity; 2005 Sep;38(6):399-408
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related loss of bone marrow pre-B- and immature B-lymphocytes in the autoimmune-prone flaky skin mutant mice.
  • We observed a rapid age-related loss of the pre-B and immature B cells.
  • It was also noted that an accumulation of early precursor populations occurs coincident with the loss of Fr.D and Fr.E bone marrow B cell populations indicating a developmental block or accumulation of pro-B cells in 7 and 10 week old fsn/fsn mice.
  • Our data suggests changes in the fsn/fsn bone-marrow microenvironment that results in senescence of B cell development.
  • [MeSH-minor] Age Factors. Animals. Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Cell Differentiation / genetics. Cell Differentiation / immunology. Cells, Cultured. Kinetics. Mice

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278144.001).
  • [ISSN] 0891-6934
  • [Journal-full-title] Autoimmunity
  • [ISO-abbreviation] Autoimmunity
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW: Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol; 2009 Dec;132(6):940-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.
  • Morphologic distinction of leukemic lymphoblasts in B acute lymphoblastic leukemia (B-ALL) from their nonneoplastic counterparts in bone marrow (hematogones) can be difficult.
  • Thus, the presence of aberrant antigen expression detectable by flow cytometry may be critical for diagnosis of B-ALL and detection of minimal residual disease.
  • Of 200 cases, 9.0% aberrantly expressed T cell-associated antigens.
  • Specific aberrancies correlate with recurrent cytogenetic abnormalities in B-ALL.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunophenotyping / methods. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Precursor Cells, B-Lymphoid / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926587.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Attarbaschi A, Mann G, König M, Steiner M, Strehl S, Schreiberhuber A, Schneider B, Meyer C, Marschalek R, Borkhardt A, Pickl WF, Lion T, Gadner H, Haas OA, Dworzak MN: Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res; 2006 May 15;12(10):2988-94
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.
  • PURPOSE: Mixed lineage leukemia (MLL) abnormalities occur in approximately 50% of childhood pro-B acute lymphoblastic leukemia (ALL).
  • However, the incidence and type of MLL rearrangements have not been determined in common ALL (cALL) and CD10+ or CD10- pre-B ALL.
  • EXPERIMENTAL DESIGN: To address this question, we analyzed 29 patients with pro-B ALL, 11 patients with CD10- pre-B ALL, 23 pre-B, and 26 cALL patients with CD10 on 20% to 80%, as well as 136 pre-B and 143 cALL patients with CD10 > or = 80% of blasts.
  • RESULTS: We found that 15 of 29 pro-B ALL, 7 of 11 CD10- pre-B ALL, and 1 of 2 French-American-British classification L1 mature B-cell leukemia cases had a MLL rearrangement.
  • However, no 11q23/MLL translocation was identified among the CD10+ pre-B and cALL patients.
  • MLL-rearranged pro-B and CD10- pre-B ALL cases had similar clinical and immunophenotypic (coexpression of CDw65 and CD15) features at initial diagnosis.
  • CONCLUSIONS: The striking similarities between the two CD10- ALL subsets imply that CD10- pre-B ALL variants may represent pro-B ALL cases that maintained the propensity to rearrange and express their immunoglobulin heavy chain rather than actual pre-B ALL forms transformed at this later stage of B-cell differentiation.
  • [MeSH-major] Chromosome Aberrations. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707593.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


84. Troeger A, Gudowius S, Escherich G, den Boer ML, Glouchkova L, Ackermann B, Meisel R, Laws HJ, Groeger M, Wessalowski R, Willers R, Harbott J, Pieters R, Goebel U, Janka-Schaub GE, Hanenberg H, Dilloo D: High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia. Br J Haematol; 2007 Nov;139(3):450-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
  • In spite of its established role in B-cell function and identification as a prognostically favourable marker in a number of malignancies, little is known about the expression pattern and prognostic significance of p75NTR in B cell precursor-acute lymphoblastic leukaemia (BCP-ALL).
  • p75NTR expression was prospectively studied on primary ALL-blasts in a cohort of paediatric patients with common ALL (n = 86) and preB-ALL (n = 34) treated within the Co-operative study group for childhood acute lymphoblastic leukaemia (CoALL) protocol, CoALL06-97.
  • In patients classified as low-risk at diagnosis, p75NTR expression was significantly higher than in high-risk patients (P = 0.001).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Nerve Tissue Proteins / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / blood. Receptors, Nerve Growth Factor / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910636.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Nerve Growth Factor
  •  go-up   go-down


85. Klein F, Feldhahn N, Mooster JL, Sprangers M, Hofmann WK, Wernet P, Wartenberg M, Müschen M: Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol; 2005 Jan 1;174(1):367-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement.
  • The BCR-ABL1 kinase expressed in acute lymphoblastic leukemia (ALL) drives malignant transformation of pre-B cells and prevents further development.
  • STI571 treatment of leukemia patients induced expression of the Ig L chain-associated transcription factors IRF4 and SPIB, up-regulation of RAG1 and RAG2, Ckappa and Clambda germline transcription, and rearrangement of Ig kappa L chain (IGK) and Ig lambda L chain (IGL) genes.
  • However, STI571-treated pre-B ALL cells expressed lambda L, but almost no kappa L chains.
  • Thus, inhibition of BCR-ABL1 in pre-B ALL cells 1) recapitulates early B cell development, 2) directly shows that IGK, KDE, and IGL genes are rearranged in sequential order, and 3) provides a model for Ig L chain gene regulation in the human.
  • [MeSH-major] B-Lymphocytes / drug effects. Gene Rearrangement, B-Lymphocyte, Light Chain / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Protein Kinase Inhibitors / therapeutic use. Stem Cells / drug effects

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611260.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / DEF6 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Guanine Nucleotide Exchange Factors; 0 / Homeodomain Proteins; 0 / IgK; 0 / Immunoglobulins; 0 / Nuclear Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / RAG2 protein, human; 0 / Transcription Factors; 0 / V(D)J recombination activating protein 2; 128559-51-3 / RAG-1 protein; 148350-00-9 / SPIB protein, human; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


86. Hewitt SL, Farmer D, Marszalek K, Cadera E, Liang HE, Xu Y, Schlissel MS, Skok JA: Association between the Igk and Igh immunoglobulin loci mediated by the 3' Igk enhancer induces 'decontraction' of the Igh locus in pre-B cells. Nat Immunol; 2008 Apr;9(4):396-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the Igk and Igh immunoglobulin loci mediated by the 3' Igk enhancer induces 'decontraction' of the Igh locus in pre-B cells.
  • Variable-(diversity)-joining (V(D)J) recombination at loci encoding the immunoglobulin heavy chain (Igh) and immunoglobulin light chain (Igk) takes place sequentially during successive stages in B cell development.
  • Using three-dimensional DNA fluorescence in situ hybridization, here we identify a lineage-specific and stage-specific interchromosomal association between these two loci that marks the transition between Igh and Igk recombination.
  • Colocalization occurred between pericentromerically located alleles in pre-B cells and was mediated by the 3' Igk enhancer.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Apr 5;296(5565):158-62 [11935030.001]
  • [Cites] Nat Immunol. 2005 Feb;6(2):198-203 [15619624.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):848-54 [11526401.001]
  • [Cites] Immunity. 2003 Feb;18(2):229-41 [12594950.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):411-22 [15004008.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4858-65 [15067064.001]
  • [Cites] EMBO J. 1984 Jun;3(6):1209-19 [6086308.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):711-20 [1900081.001]
  • [Cites] Int Immunol. 1994 Aug;6(8):1257-64 [7526894.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):637-45 [15880101.001]
  • [Cites] Semin Immunol. 2006 Feb;18(1):31-9 [16386923.001]
  • [Cites] Science. 2006 Feb 24;311(5764):1149-52 [16424298.001]
  • [Cites] Nat Cell Biol. 2006 Mar;8(3):293-9 [16434960.001]
  • [Cites] Annu Rev Immunol. 2006;24:541-70 [16551259.001]
  • [Cites] Science. 2006 Apr 14;312(5771):269-72 [16614224.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1721-32 [16785310.001]
  • [Cites] Cell. 2006 Jul 28;126(2):403-13 [16873069.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):378-87 [17334367.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5264-73 [17911612.001]
  • [Cites] Cell. 1996 Jun 14;85(6):887-97 [8681383.001]
  • [Cites] Immunity. 1996 Sep;5(3):241-52 [8808679.001]
  • [Cites] Nat Immunol. 2005 Jan;6(1):31-41 [15580273.001]
  • [Cites] Nat Immunol. 2002 May;3(5):463-8 [11967540.001]
  • (PMID = 18297074.001).
  • [ISSN] 1529-2916
  • [Journal-full-title] Nature immunology
  • [ISO-abbreviation] Nat. Immunol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL48702; United States / NIAID NIH HHS / AI / R01 AI040227; United States / NHLBI NIH HHS / HL / R01 HL048702; United States / NIAID NIH HHS / AI / R01 AI40227; United States / NIAID NIH HHS / AI / R37 AI040227-12; United States / NHLBI NIH HHS / HL / R01 HL048702-16; United States / NIAID NIH HHS / AI / R37 AI040227; United States / NHLBI NIH HHS / HL / HL048702-16; United States / NIAID NIH HHS / AI / AI040227-12; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IgK; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulins
  • [Other-IDs] NLM/ NIHMS74977; NLM/ PMC2583163
  •  go-up   go-down


87. van der Velden VH, de Bie M, van Wering ER, van Dongen JJ: Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica; 2006 May;91(5):679-82
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease.
  • We analyzed the frequency and characteristics of Vk-Jk and Vlambda-Jlambda rearrangements inpatients with precursor-B-acute lymphoblastic leukemia (ALL) and evaluated the applicability of these rearrangements as targets for minimal residual disease (MRD) detection.
  • Vk-Jk rearrangements were particularly frequent in common-ALL, children between 5-10 years, and TEL-AML1-positive patients.
  • Vk-Jk and Vlambda-Jlambda rearrangements showed a good stability between diagnosis and relapse and reached good sensitivities in real-time quantitative polymerase chain reaction analysis.
  • Our data show that Vk-Jk and Vlambda-Jlambda rearrangements can be successfully applied for MRD detection in a subset of patients with precursor-B-ALL.
  • [MeSH-major] DNA, Neoplasm / genetics. Gene Rearrangement, B-Lymphocyte, Light Chain. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627258.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


88. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM: IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia; 2010 Jul;24(7):1258-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
  • Relapse is the most common cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL) and is often difficult to predict.
  • To explore the prognostic impact of recurrent DNA copy number abnormalities on relapse, we performed high-resolution genomic profiling of 34 paired diagnosis and relapse ALL samples.
  • Recurrent lesions detected at diagnosis, including PAX5, CDKN2A and EBF1, were frequently absent at relapse, indicating that they represent secondary events that may be absent in the relapse-prone therapy-resistant progenitor cell.
  • A targeted copy number screen in an unselected cohort of 131 precursor B-ALL cases, enrolled in the dexamethasone-based Dutch Childhood Oncology Group treatment protocol ALL9, revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates.
  • Consequently, IKZF1 deletion status allowed the prospective identification of 53% of the relapse-prone NHR-classified patients within this subgroup and, therefore, serves as one of the strongest predictors of relapse at the time of diagnosis with high potential for future risk stratification.
  • [MeSH-major] Gene Deletion. Ikaros Transcription Factor / genetics. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics


89. Qiu Y, Morii E, Tomita Y, Zhang B, Matsumura A, Kitaichi M, Okumura M, Aozasa K: Prognostic significance of pre B cell leukemia transcription factor 2 (PBX2) expression in non-small cell lung carcinoma. Cancer Sci; 2009 Jul;100(7):1198-209
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of pre B cell leukemia transcription factor 2 (PBX2) expression in non-small cell lung carcinoma.
  • Previous studies on the mammary carcinoma cell line have shown that the pre B cell leukemia transcription factor 1 (PBX1) was a transcription factor for valosin-containing protein (VCP), which is involved in invasion and metastasis of cancers.
  • The roles of PBX1 and PBX2, a highly homologous transcription factor to PBX1, for expression of VCP were examined in the cell lines from non-small cell lung cancer (NSCLC).
  • The effects of PBX1 and PBX2 on VCP expression were examined with siRNA in A549 and PC14 NSCLC cell lines.
  • Expression levels of VCP mRNA significantly decreased when PBX2 but not PBX1 expression was knocked down in NSCLC cell lines.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Homeodomain Proteins / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Adenosine Triphosphatases / genetics. Adenosine Triphosphatases / metabolism. Adult. Aged. Cell Cycle Proteins / genetics. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. RNA, Small Interfering / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356220.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Homeodomain Proteins; 0 / PBX2 protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / CDC48 protein
  •  go-up   go-down


90. Tchinda J, Volpert S, Berdel WE, Büchner T, Horst J: Novel three-break rearrangement and cryptic translocations leading to colocalization of MYC and IGH signals in B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2006 Mar;165(2):180-4
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel three-break rearrangement and cryptic translocations leading to colocalization of MYC and IGH signals in B-cell acute lymphoblastic leukemia.
  • Reciprocal translocations involving the MYC locus and immunoglobulin heavy chain (IGH) and light chain (IgK and IgL) loci are characteristic for non-Hodgkin lymphomas, especially Burkitt lymphoma, and have been described in B-cell acute lymphoblastic leukemia (B-ALL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Rearrangement. Genes, myc. Immunoglobulin Heavy Chains / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527615.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


91. Niizuma H, Fujii K, Sato A, Fujiwara I, Takeyama J, Imaizumi M: PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Dec;49(7):990-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia.
  • Hypercalcemia in childhood acute lymphoblastic leukemia (ALL) is rare and occasionally associated with parathyroid hormone-related protein (PTHrP).
  • We report two children with precursor B ALL who had marked hypercalcemia (15.8 and 16.6 mg/dl, respectively) and disseminated osteolysis.
  • These findings suggest that increased osteoclastic bone resorption via stimulation with TNF-alpha and IL-6 may be mechanism causing PTHrP-independent hypercalcemia in some patients with precursor B ALL lacking CD19 expression.
  • [MeSH-major] Bone Resorption / complications. Cytokines / blood. Diphosphonates / administration & dosage. Hypercalcemia / complications. Parathyroid Hormone-Related Protein / blood. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 16496289.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Bone Density Conservation Agents; 0 / Cytokines; 0 / Diphosphonates; 0 / Parathyroid Hormone-Related Protein; 90032-33-0 / deoxypyridinoline
  •  go-up   go-down


92. Hinman RM, Nichols WA, Diaz TM, Gallardo TD, Castrillon DH, Satterthwaite AB: Foxo3-/- mice demonstrate reduced numbers of pre-B and recirculating B cells but normal splenic B cell sub-population distribution. Int Immunol; 2009 Jul;21(7):831-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Foxo3-/- mice demonstrate reduced numbers of pre-B and recirculating B cells but normal splenic B cell sub-population distribution.
  • B cell antigen receptor (BCR) cross-linking promotes proliferation and survival of mature B cells.
  • Phosphoinositide-3-kinase-mediated down-regulation of pro-apoptotic and anti-mitogenic genes such as the Foxo family of transcription factors is an important component of this process.
  • While Foxo1, Foxo3 and Foxo4 bind the same DNA sequence, the differential control of their expression upon B cell activation suggests that they may have unique functions in the B lineage.
  • To begin to address this issue, we evaluated B cell development and function in Foxo3-/- mice.
  • No effect of Foxo3 deficiency was observed with respect to the following parameters in the splenic B cell compartment: sub-population distribution, proliferation, in vitro differentiation and expression of the Foxo target genes cyclin G2 and B cell translocation gene 1.
  • A significant reduction in pre-B cell numbers was also observed in Foxo3-/- bone marrow.
  • Thus, Foxo3 makes a unique contribution to B cell development, B cell localization and control of Ig levels.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 May 1;149(3):657-66 [10791979.001]
  • [Cites] Immunity. 2004 Aug;21(2):203-13 [15308101.001]
  • [Cites] Immunol Rev. 2000 Aug;176:19-29 [11043765.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):629-34 [10880363.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Eur J Immunol. 2002 Apr;32(4):982-93 [11920564.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1647-52 [12070292.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27449-67 [11956189.001]
  • [Cites] Nat Immunol. 2002 Aug;3(8):780-6 [12118249.001]
  • [Cites] Sci STKE. 2003 Mar 4;2003(172):RE5 [12621150.001]
  • [Cites] Science. 2003 Jul 11;301(5630):215-8 [12855809.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1623-9 [12902457.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4166-77 [12912915.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):175-84 [14734530.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):10058-71 [15509806.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Jan;3(1):24-36 [2069907.001]
  • [Cites] Cell. 1992 Mar 6;68(5):855-67 [1547487.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1663-70 [1373383.001]
  • [Cites] J Exp Med. 1995 Apr 1;181(4):1519-26 [7699333.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):195-202 [9010221.001]
  • [Cites] Annu Rev Immunol. 1997;15:707-47 [9143705.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Nature. 1999 Apr 15;398(6728):630-4 [10217147.001]
  • [Cites] J Exp Med. 1999 May 3;189(9):1513-8 [10224292.001]
  • [Cites] Annu Rev Immunol. 1999;17:555-92 [10358768.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):16741-6 [10358014.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17179-83 [10358075.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421-6 [10377430.001]
  • [Cites] Science. 1999 Sep 24;285(5436):2129-33 [10497131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11836-41 [10518537.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):291-301 [15657295.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4161-71 [15778376.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2317-29 [15688014.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2711-21 [16493026.001]
  • [Cites] Int Immunol. 2006 Apr;18(4):603-11 [16497829.001]
  • [Cites] Immunity. 2006 Oct;25(4):545-57 [17000121.001]
  • [Cites] J Immunol. 2007 Jan 15;178(2):740-7 [17202334.001]
  • [Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(7):2676-86 [17242183.001]
  • [Cites] Blood. 2007 May 1;109(9):3749-56 [17234743.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3839-3854 [17353275.001]
  • [Cites] Reproduction. 2007 May;133(5):855-63 [17616716.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7081-91 [17496928.001]
  • [Cites] Mol Med. 2007 Nov-Dec;13(11-12):561-6 [17873969.001]
  • [Cites] Immunity. 2008 Jan;28(1):122-33 [18164221.001]
  • [Cites] Nat Immunol. 2008 May;9(5):513-21 [18391955.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):613-22 [18469817.001]
  • [Cites] Nat Immunol. 2008 Jun;9(6):623-31 [18488031.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2980-9 [18713968.001]
  • [Cites] Nat Immunol. 2008 Dec;9(12):1388-98 [18978794.001]
  • [Cites] Nature. 2004 Jan 22;427(6972):355-60 [14737169.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2975-80 [14978268.001]
  • [Cites] Blood. 2004 Aug 1;104(3):784-7 [15069012.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34741-9 [15184386.001]
  • [Cites] Immunity. 2000 Jul;13(1):25-35 [10933392.001]
  • (PMID = 19502585.001).
  • [ISSN] 1460-2377
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR024196-04; United States / NCRR NIH HHS / RR / 1K26RR024196; United States / NCRR NIH HHS / RR / K26 RR024196-04; United States / NIAID NIH HHS / AI / AI049248; United States / NCRR NIH HHS / RR / K26 RR024196; United States / NIAID NIH HHS / AI / T32 AI 005284-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Butadienes; 0 / Ccng2 protein, mouse; 0 / Chromones; 0 / Cyclin G2; 0 / Cyclins; 0 / Enzyme Inhibitors; 0 / Forkhead Transcription Factors; 0 / FoxO3 protein, mouse; 0 / FoxO4 protein, mouse; 0 / Foxo1 protein, mouse; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Interleukin-7; 0 / Morpholines; 0 / Nitriles; 0 / Receptors, Antigen, B-Cell; 0 / U 0126; 0 / anti-IgM; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 83HN0GTJ6D / Cyclosporine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Other-IDs] NLM/ PMC2699488
  •  go-up   go-down


93. Jiang JG, Roman E, Nandula SV, Murty VV, Bhagat G, Alobeid B: Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement. Leuk Lymphoma; 2005 Aug;46(8):1223-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement.
  • Congenital acute leukemia is a rare form of childhood leukemia, in which lineage conversion at relapse is very rarely reported.
  • Here we describe a case of congenital B-cell acute lymphoblastic leukemia (B-ALL) with t(4;11) and t(1;6) translocations, which at relapse underwent a switch to monocytic lineage with persistence of the original cytogenetic translocations and clonal rearrangement of the JH gene.
  • Similar to the other described cases of congenital acute leukemia with lineage conversion, our case had a MLL gene rearrangement and followed an aggressive clinical course.
  • [MeSH-major] Burkitt Lymphoma / genetics. Leukemia, Myeloid, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Cell Lineage. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 4 / genetics. Chromosomes, Human, Pair 6 / genetics. Cytogenetic Analysis. Disease Progression. Fatal Outcome. Female. Histone-Lysine N-Methyltransferase. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin J-Chains / genetics. Immunophenotyping. Infant, Newborn. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085566.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin J-Chains; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


94. Stachel D, Albert M, Meilbeck R, Paulides M, Schmid I: Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia. Oncol Rep; 2007 Jan;17(1):147-52
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
  • Pathological angiogenesis is increasingly recognized to be an important feature of pathogenesis in solid tumors and also in leukemias.
  • Specific blockers of angiogenesis are now being introduced into early clinical trials with encouraging results.
  • Vascular endothelial growth factor (VEGF) seems to play a central role in tumor angiogenesis and is associated with a poor prognosis in both solid tumors and adult leukemias.
  • In pediatric acute lymphocytic leukemia however, the expression of angiogenic molecules and its relation to prognosis and relapse are unknown.
  • Therefore, we prospectively analyzed 46 pediatric patients with precursor B cell acute lymphocytic leukemia by semi-quantitative RT-PCR for expression of the angiogenic molecules VEGF, VEGF-C, iNOS and TGF-beta and correlated relapse and survival data with the expression of these factors.
  • Angiogenic factors are expressed in the bone marrow of patients with pediatric B cell precursor ALL and VEGF is a potential candidate for therapeutic intervention as it is significantly higher expressed in children with late relapses.
  • The mRNA expression of iNOS in the surviving children possibly reflects an increased activity of the immune system against the leukemia which leads to a superior survival.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Burkitt Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adolescent. Bone Marrow Cells / metabolism. Child. Child, Preschool. Female. Fibroblast Growth Factor 2 / biosynthesis. Fibroblast Growth Factor 2 / genetics. Humans. Infant. Male. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Nitric Oxide Synthase Type II / biosynthesis. Nitric Oxide Synthase Type II / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic. Transforming Growth Factor beta / biosynthesis. Transforming Growth Factor beta / genetics. Vascular Endothelial Growth Factor A / biosynthesis. Vascular Endothelial Growth Factor A / genetics. Vascular Endothelial Growth Factor C / biosynthesis. Vascular Endothelial Growth Factor C / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143492.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


95. Airoldi I, Cocco C, Di Carlo E, Disarò S, Ognio E, Basso G, Pistoia V: Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res; 2006 Apr 15;66(8):3978-80
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells.
  • The aim of this study was to investigate (i) whether the IL-12Rbeta2 gene is silenced in B-cell acute lymphoblastic leukemia (B-ALL) cells, and (ii) what the functional implications of such silencing for tumor growth are.
  • Here, we show that although mature B cells expressed both chains of the IL-12R, normal pro-B and pre-B cells failed to express the IL-12Rbeta2 chain.
  • Similarly, primary tumor cells from pediatric pro-B, early pre-B, and pre-B ALL (30 cases) did not express the IL-12Rbeta2 chain.
  • Such methylation was not detected in normal early B cells that when differentiated into mature B cells expressed the IL-12Rbeta2 gene.
  • Detection of IL-12Rbeta2 mRNA and protein in the tumorigenic 697 pre-B-ALL cell line allowed to perform functional experiments in severe combined immunodeficient/nonobese diabetic mice receiving 697 cells with or without human recombinant IL-12 (hrIL-12).
  • [MeSH-major] Burkitt Lymphoma / genetics. DNA Methylation. Receptors, Interleukin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618714.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / IL12RB2 protein, human; 0 / Il12rb2 protein, mouse; 0 / Receptors, Interleukin; 0 / Receptors, Interleukin-12
  •  go-up   go-down


96. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E: Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol; 2007 Feb;136(3):400-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines.
  • Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children.
  • This study found that Wnt3A induced beta-catenin accumulation in both primary B-ALL cells and B-ALL leukaemia cell lines.
  • Further, Wnt3A was shown to induce nuclear translocation of beta-catenin and TCF/Lef-1 dependent transcriptions in the B-ALL cell line Nalm-6.
  • Functional analyses showed that Wnt3A inhibited the proliferation of several, but not all, B-ALL cell lines studied.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Signal Transduction / physiology. Wnt Proteins / pharmacology
  • [MeSH-minor] Blotting, Western / methods. Cell Line, Tumor. Cell Proliferation. Gene Expression Profiling. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transcription Factors / genetics. Transcription Factors / metabolism. Tumor Cells, Cultured. Wnt3 Protein. Wnt3A Protein. beta Catenin / genetics. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156404.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / WNT3A protein, human; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / beta Catenin
  •  go-up   go-down


97. Reid GS, She K, Terrett L, Food MR, Trudeau JD, Schultz KR: CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood; 2005 May 1;105(9):3641-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response.
  • Pediatric precursor B acute lymphoblastic leukemia (B-ALL) cells express low levels of costimulatory molecules and are generally poor stimulators of T-cell responses.
  • In this study, we evaluated the impact of CpG stimulation on precursor B-ALL cell lines and pediatric patient-derived samples.
  • In contrast to both nonleukemic B-cell precursors and mature B cells, the response of precursor B-ALL cells was characterized by increased CD40 expression but only small changes in CD86 levels and no induction of CD80 expression.
  • These results demonstrate the functional relevance of CpG stimulation of precursor B-ALL cells and provide a rational basis for study of these agents for use in treatment of this disease.
  • [MeSH-major] Dinucleoside Phosphates / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Th1 Cells / immunology
  • [MeSH-minor] Animals. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Cell Line, Tumor. DNA-Binding Proteins / physiology. Humans. Interleukins / biosynthesis. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Oligodeoxyribonucleotides / pharmacology. Receptors, Cell Surface / physiology. T-Lymphocyte Subsets / immunology. Toll-Like Receptor 9. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15650062.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Dinucleoside Phosphates; 0 / Interleukins; 0 / Oligodeoxyribonucleotides; 0 / Receptors, Cell Surface; 0 / TLR9 protein, human; 0 / Tlr9 protein, mouse; 0 / Toll-Like Receptor 9; 2382-65-2 / cytidylyl-3'-5'-guanosine
  •  go-up   go-down


98. Ju X, Li D, Shi Q, Hou H, Sun N, Shen B: Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2009 Jan;26(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia.
  • The analysis of differential microRNA expression profiles may be a powerful tool to allow us insight on the mechanisms of childhood B-cell precursor acute lymphoblastic leukemia (pre-B-ALL).
  • The present study provides an informative profile of the expression of miRNAs in pre-B-ALL using two independent and quantitative methods: miRNA chip and qRT-PCR of mature miRNA from 40 newly diagnosed pre-B-ALL children.
  • Additionally, putative hematopoiesis-specific target genes were analyzed with informatics technique.
  • Both approaches showed that miR-222, miR-339, and miR-142-3p were dramatically overexpressed in pre-B-ALL patients, and downregulation of hsa-miR-451 and hsa-miR-373* was confirmed.
  • The results of this study offer a comprehensive and quantitative profile of miRNA expression in pre-B-ALL and their healthy counterpart, suggesting that miRNAs could play a primary role in the disease itself.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. MicroRNAs / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Child. Child, Preschool. Computational Biology. Gene Expression Profiling. Hematopoiesis / genetics. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19206004.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MIRN222 microRNA, human; 0 / MIRN373 microRNA, human; 0 / MIRN451 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


99. Tuğcu A, Yildirimtürk O, Aytekin S: [The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardiographic findings]. Turk Kardiyol Dern Ars; 2009 Mar;37(2):112-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardiographic findings].
  • OBJECTIVES: We investigated the value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) to diagnose diastolic heart failure (DHF) without left ventricular (LV) hypertrophy.
  • STUDY DESIGN: The study included 33 patients (17 males, 16 females) with DHF, who had acute pulmonary congestion and LV ejection fraction (EF) >50% on admission, and were stable for at least six months of follow-up.
  • [MeSH-major] Heart Failure, Diastolic / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Turk Kardiyol Dern Ars. 2009 Sep;37(6):439-40 [20019465.001]
  • (PMID = 19404033.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] tur
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


100. Safa M, Kazemi A, Zand H, Azarkeivan A, Zaker F, Hayat P: Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues. Apoptosis; 2010 Feb;15(2):196-203
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory role of cAMP on doxorubicin-induced apoptosis in pre-B ALL cells through dephosphorylation of p53 serine residues.
  • Exposure of cells to chemotherapeutic drug doxorubicin, a DNA-damaging agent, induces an increase in the levels and activity of the wild-type p53 protein.
  • Here we show that elevation of cAMP in pre-B acute lymphoblastic leukemia NALM-6 cells significantly attenuated phosphorylation state of p53 at Ser6, Ser9, Ser15, Ser20, Ser37, Ser46 and Ser392 upon exposure to doxorubicin.
  • [MeSH-major] Apoptosis / drug effects. Cyclic AMP / pharmacology. Doxorubicin / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Serine / metabolism
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Caspase 3 / metabolism. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Checkpoint Kinase 2. DNA Damage. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Leukemic / drug effects. Humans. Intracellular Space / drug effects. Intracellular Space / metabolism. Okadaic Acid / pharmacology. Phosphoprotein Phosphatases / metabolism. Phosphorylation / drug effects. Phosphoserine / metabolism. Protein Phosphatase 1 / metabolism. Protein Phosphatase 2 / metabolism. Protein-Serine-Threonine Kinases / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism. bcl-2-Associated X Protein / metabolism

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. L-SERINE .
  • Hazardous Substances Data Bank. OKADAIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882354.001).
  • [ISSN] 1573-675X
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 17885-08-4 / Phosphoserine; 1W21G5Q4N2 / Okadaic Acid; 452VLY9402 / Serine; 80168379AG / Doxorubicin; E0399OZS9N / Cyclic AMP; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.1.3.16 / Phosphoprotein Phosphatases; EC 3.1.3.16 / Protein Phosphatase 1; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.16 / protein phosphatase 2C; EC 3.4.22.- / Caspase 3
  •  go-up   go-down






Advertisement